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Chapter I                                                                                Introduction
CHAPTER – I
INTRODUCTION 
 For many decades treatment of an acute disease (or) a chronic illness has been
mostly  accomplished  by  delivery  of  drugs  to  patients  using  various  pharmaceutical
conventional dosage forms (such as tablets, capsules, pills, suppositories, creams, ointments,
liquids, aerosols and injectables as drug carriers).  [1] Even today conventional drug delivery
system occupies most of the part in a prescription as well as drug store. This type of drug
delivery system is known to provide a prompt release of drug. 
Therefore,  to  achieve  as  well  as  to  maintain  the  drug  concentration  within  the
therapeutically effective range needed for treatment, it is often necessary to take this type of
drug delivery system several times a day.  [1] This results in significant fluctuations in drug
release. (Figure: 1)                              Figure: 1
DISADVANTAGES OF CONVENTIONAL DOSAGE FORM [2]
1) Poor patient compliance- increased chances of missing the dose of a drug with short
half life for which frequent administration is necessary.
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2) A typical  peak-valley  plasma concentration-time  profile  is  obtained  which  makes
attainment of steady state condition is difficult.
3) The unavoidable fluctuations in the drug concentration may lead to under-medication
or  over-medication  as the Css values fall or rise beyond the therapeutic range 
4) The fluctuating drug levels may lead to precipitation of adverse effects especially of a
drug with small therapeutic index whenever over-medication.
To overcome the above disadvantages, development of drug delivery systems capable
of controlling the rate of drug delivery, sustaining the duration of therapeutic action and/or
targeting the delivery of drug to a particular tissue [1].
They are as follows [3] 
1. Delayed release.
2. Repeat action.
3. Prolonged release.
4. Sustained Release.
5. Extended release.
6. Controlled Release (Rate controlled).
7. Modified release.
1) Delayed Release 
Delayed  Release  indicates  the  drug  is  not  being  released  immediately  following
administration but at later time. Ex: enteric coated tablets; pulsatile release capsules.
2) Repeat action
   Repeat action indicates that an indivual dose is released fairly soon after administration and
second or third doses are subsequently at intermittent intervals.
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3) Prolonged release
Prolonged release indicates that  the drug is  provided for absorption over  a  longer
period of time than from a conventional dosage form. However there is an implication that
onset is delayed because of an overall slower release rate from the dosage form.
 
4) Sustained Release 
Sustained  Release  indicates  an  initial  release  of  drug  sufficient  to  provide  a
therapeutic  dose  soon  after  administration  and  then  a  gradual  release  over  the  extended
period.
5) Extended Release 
Sustained release dosage forms release drug slowly, so that plasma concentrations are
maintained at a therapeutic level for a prolonged period of time. (Usually between 8 and 12
hours) 
6) Controlled Release
Controlled  release  dosage  forms  release  the  drug  at  a  constant  rate,  which  is
predictable and also the release rate  is  reproducible from one unit  to  another.  It  provide
plasma concentrations that remain invariant with time.
7) Modified Release
Modified Release dosage forms are defined by the USP as those whose drug release
characteristics of  time course and for location are choosen to accompolish therapeutic  or
convenience  objectives  not  offered  by  conventional  forms  whereas  an  extended  release
dosage form allows a 2 fold reduction in dosing frequency or increase in patient compliance
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or therapeutic performance. It  is  interesting to note that  the USP considers that the terms
controlled release prolonged release and sustained release are interchangeable with extended
release. 
CLASSIFICATION OF CONTROLLED DRUG DELIVERY SYSTEMS (DDS) [2] 
1. Rate-preprogrammed drug delivery systems. 
2. Activation-modulated drug delivery systems.
3. Feedback-regulated drug delivery systems. 
4. Site-targeting drug delivery systems.
TARGETED or SITE-SPECIFIC DDS:
Targeted DDS refers to systems that place the drug at or near the receptor site or site 
of action.  Targeted drug delivery implies selective and effective localization of drug into the 
target(s) at therapeutic concentrations with limited access to target sites. [4]
A targeted drug delivery system is preferred in the following situations:
 Pharmaceutical: drug instability, low solubility.
 Pharmacokinetic: short half-life, large volume of distribution, poor 
absorption.
 Pharmacodynamic: low solubility, low therapeutic index.
Targeted drug delivery may provide maximum therapeutic activity by preventing drug
degradation or inactivation during transit to the target sites. Meanwhile, it can protect the
body from the adverse effects because of inappropriate disposition, and minimize toxicity of
potent  drugs  by  reducing  dose.  An  ideal  targeted  delivery  system  should  be  nontoxic,
biocompatible,  biodegradable  and  physicochemically  stable  in  vivo  and  in  vitro.  The
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preparation  of  the  delivery  system  must  be  reasonably  simple,  reproducible  and
cost-effective.
Site-targeted DDSs have also been characterized as-
• Passive targeting: refers to natural or passive disposition of a drug-carrier based on 
the physiochemical characteristics of the system in relation to the body.
• Active targeting: refers to alteration of the natural disposition of the drug carrier, 
directing it to specific cells, tissues or organs; for e.g. use of  ligands or monoclonal 
antibodies which can target specific sites.
• Inverse targeting
• Ligand mediated targeting
• Physical targeting (Triggered release)
• Dual targeting
• Double targeting
• Combination targeting [5]
 Site-targeted DDS can be classified into three broad categories-
1. First-order targeting: refers to DDS that delivers the drug to the capillary bed or the 
active site.
2. Second-order targeting: refers to DDS that delivers the drug to a specific cell type 
such as the tumour cells and not to the normal cells.
3. Third-order targeting: refers to DDS that delivers the drug intracellularly.
Drug  targeting  often  requires  carriers  for  selective  delivery  and  can  serve  following
purposes-
1. Protect the drug from degradation after administration.
2. Improve transport or delivery of drug to cells.
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3. Decrease clearance of drug.
4. Combination of the above
Carriers for drug targeting are of two types-
• Carriers covalently bonded to drug: where the drug release is required for
pharmacological activity.
• Carriers not covalently bonded to drug:  where simple uncoating of the
drug is required for pharmacological activity. E.g. liposomes.
The various carriers used for drug targeting are-
a. Polymeric carriers,
b. Albumin,
c. Lipoproteins,  
d. Liposomes, 
e. Niosomes,
f. Microspheres,
g. Nanoparticles,
h. Antibodies,
i. Cellular carriers and 
j. Macromolecules.
COLLOIDAL DRUG CARRIERS: [6]
Colloidal  drug delivery systems include micro-  and nanoparticles,  macromolecular
complexes (e.g. lipoproteins), liposomes and niosomes. In many cases, colloidal carriers are
used to improve stability of the drug either  in  biological  fluids  or  in the formulation,  to
develop extended-release systems with targeting features and/or to enhance the therapeutic
efficacy  and  reduce  drug  toxicity  by  modifying  the  distribution  and  controlling  the
disposition of the drug. [3] 
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CHAPTER – II
VESICULAR SYSTEMS –REVIEW
The quest never ends. From the very beginning of the human race; the quest is going
on for newer and better alternatives; and in case of drugs it will continue; continue till we
find  a  drug  with  maximum  efficacy  and  no  side  effects.  Many  drugs,  particularly
chemotherapeutic agents, have narrow therapeutic window, and their clinical use is limited
and compromised by dose limiting toxic effect. Thus,  the therapeutic effectiveness of the
existing drugs is improved by formulating them in an advantageous way.
NOVEL DRUG DELIVERY SYSTEM (NDDS) [7]
In the past few decades, considerable attention has been focussed on the development
of new drug delivery system (NDDS). The NDDS should ideally fulfil two prerequisites.
• Firstly, it should deliver the drug at a rate directed by the needs of the body,
over the period of the treatment.
• Secondly, it should channel the active entity to the site of action.
Conventional dosage forms including prolonged release dosage forms are unable to
meet none of these. At present, no available drug delivery system behaves ideally, but sincere
attempts  have  been  made  to  achieve  them  through  various  novel  approaches  in  drug
delivery. [1] 
Approaches are being adapted to achieve this goal, by paying considerable attention
either to control the distribution of drug by incorporating it in a carrier system, or by altering
the structure of the drug at the molecular level, or to control the input of the drug into the
bioenvironment to ensure an appropriate profile of distribution.
NDDS aims at providing some control, whether this is of temporal or spatial nature,
or both, of drug release in the body. Novel drug delivery attempts to either sustain drug action
at a predetermined rate, or by maintaining a relatively constant, effective drug level in the
body without concomitant minimization of undesirable side effects. It can also localize drug
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action by spatial placement of controlled release systems adjacent to, or in the diseased tissue
or organ; or target drug action by using carriers or chemical derivatization to deliver drug to
particular cell type.    
A number of NDDS have emerged encompassing various routes of administration, to
achieve controlled and targeted drug delivery. Encapsulation of drug in vesicular structure is
one such system, which can be predicted to prolong the existence of the drug in systemic
circulation, and reduce the toxicity, if selective uptake can be achieved.
The vesicular  systems are highly ordered  assemblies  of  one  or  several  concentric
bilayers  formed,  when  certain  amphiphilic  building  blocks  are  confronted  with  water.
Vesicles can be formed from a diverse range of amphiphilic building blocks. Biologic origin
of these vesicles was first reported in 1965 by Bingham, and was given the name Bingham
bodies.
COLLOIDAL DISPERSIONS:
The main therapeutic and commercial aims of colloidal drug carriers (CDC) include-
• Enhancement of oral bioavailability
• Decrease in variability and food dependency
• Development of i.v. injectable formulations
• Drug targeting to specific tissues (with reduction of general toxicity)
• Life cycle management (protection by proprietary formulation techniques).
VESICULAR SYSTEMS:
In recent years, vesicles have become the vehicle of choice in drug delivery. Lipid
vesicles were found to be value of immunology, membrane biology, diagnostic techniques,
and most recently, genetic engineering. Vesicles can play a major role in modelling biological
membranes, and in the transport and targeting of active agents.
Biological  membranes  form the ubiquitous  delimiting structures that  surround and
compartmentalize all cells and organelles. The bilayer arrangement of lipids is perhaps the
only  organizational  feature  that  is  common  to  all  biological  membranes.  Numerous
theoretical  models of membrane structure have appeared since the publication of the cell
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theory by Schleiden and Sehwann in 1839. Experimental  models provide insight into the
national  dynamics  and  static  structures  of  some  isolated  compartments  of  biological
membranes. Lipid vesicles are just one type of many experimental models of biomembranes.
Although developed for basic research, many technological innovations have arisen from the
applications  of  these  models.  Lipid  vesicles  have  evolved  successfully,  as  vehicles  for
controlled drug delivery.
ADVANTAGES OF VESICULAR SYSTEMS: [8]
♦ Efficient method for delivery of drug directly to the site of infection.
♦ Reduction of drug toxicity with no adverse effects.
♦ Reduces the cost of the therapy by improved bioavailability of the medication,
♦ Incorporate both hydrophilic and lipophilic drugs.
♦ Delay drug elimination of rapidly meatbolizable drugs
♦ Function as sustained release systems.
♦ Solves the problems of drug insolubility, instability, and rapid degradation.
TYPES OF VESICULAR SYSTEMS:
Various types of vesicular systems are as follows,
• Liposomes
• Niosomes
• Transferosomes
• Pharmacosomes
• Enzymosomes
• Virosomes
• Ufasomes
• Cryptosomes
• Emulsomes
• Discomes
• Aquasomes
• Ethosomes
• Genosomes
• Photosomes
• Erythrosomes
• Hemosomes
• Proteosomes
• Vesosomes
• Archaeosomes
• Apsasomes
• Colloidosomes
• Cubasomes
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LIPOSOMES: [2]
Liposomes (meaning lipid body) are spherical microscopic vesicles compose of one or
more concentric lipid bilayers, separated by water or aqueous buffer compartments with a
diameter ranging from 25nm to 10000nm.  Self assembly of phospholipid molecules in an
aqueous environment results in the formation of liposomes [9]. 
They  are  commonly  composed  of  one  or  more  amphiphilic  phospholipid  bilayer
membranes (and thus also called as  phospholipid vesicles)  that can entrap both hydrophilic
and  hydrophobic  drugs.  Hydrophilic  drugs  are  entrapped  in  the  aqueous  centre  of
liposome while the liposome wall, being phospholipid membrane can hold hydrophobic
agents. There are a number of components present in liposomes,  with phospholipids and
cholesterol being main ingredients.  The phospholipids used for making liposomes include
phosphatidylcholines  (PC),  phosphatidylethanolamines  (PE)  and phosphatidylserines  (PS).
Besides,  phospholipids,  sphingolipids,  glycolipids and sterols can also be used to prepare
liposomes.  These  vesicles  are  exploited  to  achieve  altered  drug  pharmacokinetics  and
targeted therapies.
     
      Inner aqueous environment
      Phospholipid bilayer    
 
Figure: 2 Structure of liposomes.
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CLASSIFICATION OF LIPOSOMES:
Depending upon their size and structure, liposomes are classified as follows,
1. MLV (multilamellar vesicles): These liposomes are made of series of concentric
bilayers (5-20 layers) of lipids enclosing a small internal volume. They have a
diameter of more than 5000nm.
2. OLV  (oligolamellar  vesicles):   These  are  made  of  2  to  5  bilayers  of  lipids
surrounding a large internal volume. They have a diameter of 100- 1000nm.
3. MVV (multilvesicular vesicles):  These have multicompartmental  structures and
have diameter more than 1000nm. 
4. ULV (unilamellar vesicles):  These are made of single bilayer of lipids. These may
be further classified on the basis of their size into-
• SUV (small unilamellar vesicles) of size 20 to 40nm.
• MUV (medium unilamellar vesicles) of size 40 to 80nm.
• LUV (large unilamellar vesicles) of size 100 to 1000nm.
• GUV (giant unilamellar vesicles) of size greater than 1000nm.
Liposomes possess special characteristics such as-
1. Biodegradable and non-toxic.
2. Do not interact with drug or alter its activity.
3. Controlled hydration.
4. Control drug delivery rate: which in turn prevents degradation of drug, enhances
their  biological  half-life  and  thus  prolongs  pharmacological  effects.
E.g. progesterone and cisplatin.
5. act as potent adjuvants to augment the immune response to recombinant protein
vaccines. E.g. virosomes.
6. Ability to incorporate both water- and oil-soluble drugs.
7. Ability to protect labile compounds.
8. Available in a variety of sizes.
9. Serve as efficient solubilising vehicles for drugs with poor aqueous solubility such
as alphaxalone, camptothecin, tacrolimus, econazole and paclitaxel.
10. Liposomes can be used for passive or active tissue targeting. 
Disadvantages of liposomes:
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 Liposomal formulations are expensive
 Liposomes are chemically unstable because of their predisposition to oxidative
degradation.
 Tend to aggregate or lose entrapped drug during storage.
 Cannot be sterilizes by irradiation or by heat.
 Can be taken by the RES before reaching their target organ.
  High density lipoproteins tend to interact with liposomes in vivo leading to a loss
of encapsulated species.
 Purity of natural phospholipids is another criterion for adoption of liposomes as
drug delivery vehicles.
                       Due to the above limitations of liposomes newer vesicular system developed
known as “Niosomes” using non- ionic surfactants.
NIOSOMES:
Niosomes  are  non-phospholipid  vesicular  alternative  to  liposomes.  Niosomes  are
osmotically stable unilamellar or multilamellar vesicular systems obtained on hydration of
synthetic non-ionic surfactants.  The success achieved with liposomal systems stimulated the
search for other vesicle-forming amphiphiles  which led to  the development  of niosomes.
Non-ionic surfactants were among the first alternative materials studied, and a large number
of surfactants have since been found to self-assemble into closed bilayer vesicles that are
used for drug delivery. [9]
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TRANFEROSOMES [10]
                Liposomal as well as niosomal systems are not suitable for transdermal delivery
because of the poor skin permeability, breaking of vesicles, leakage of drug, aggregation and
fusion  of  vesicles.  To  overcome  these  problems,  a  new  type  of  carrier  system  called
tranferosomes has recently being introduced which is capable of transdermal delivery of low
as well as high molecular weight drugs.
Transferosomes  are  specially  optimized,  ultradeformable  (ultraflexible),  lipid
supramolecular  aggregates,  which  are  able  to  penetrate  the  mammalian  skin intact.  Each
transferosome consists of at least one inner aqueous compartment which is surrounded by a
lipid bilayer with specially tailored properties, due to the incorporation of ‘‘edge activators’’
into the vesicular membrane. Surfactants such as sodium cholate, sodium deoxycholate, span
80 and tween 80 have been used as edge activators. It  was suggested that transferosomes
could respond to external stress by rapid shape transformations requiring low energy. These
novel cariers are applied in the form of semidilute suspension without occlusion. Due to their
deformability,  transferosomes  are  good  candidates  for  the  noninvasive  delivery of  small,
medium and large size drugs. 
LIMITATIONS:
1. Transferosomes are chemically unstable because of the predisposition to oxidative
degradation.
2. Lack  of  purity of  the natural  phospholipids  comes  in  the  way of  adoption of
transferosomes as drug delivery vehicles
3. Transferosomes formulations are expensive to prepare.
PHARMACOSOMES:
                       The limitations of tranferosomes as that of liposomes can be overcome by the
pharmacosomes  approach.  These  are  defined  as  colloidal  dispersions  of  drugs  covalently
bound to lipids and may exist  as ultra fine vesicular,  micellar (or) hexagonal aggregates,
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depending on the chemical structure of drug – lipid complex.  Many constraints of various
classical vesicular drug delivery systems, such as problems of drug incorporation, leakage
from the carrier, or insufficient shelf life can be avoided by the pharmacosome approach.
The idea for the development of the vesicular pharmacosome is based on surface and
bulk interactions of lipids with drug. Any drug processing an active hydrogen atom (-COOH,
-OH, -NH2, etc) can be esterified to the lipid, with or without spacer chain. Synthesis of such
a compound may be guided in such a way that strongly results in an amphiphilic compound,
which will facilitate membrane, tissue or cell wall transfer, in the organism.
ENZYMOSOMES: 
Liposomal construct engineered to provide a mini bioenvironment in which enzymes
are covalently immobilized or couples  to the surface of the liposomes.  Used for  targeted
delivery to tumour cells. 
VIROSOMES:
Liposomes spiked with virus glycoprotein, incorporated into the liposomal bilayers
based on retro viruses derived lipids. Used for immunological adjuvants.
UFASOMES:
Vesicles  enclosed  by fatty acids  obtained  from long chain fatty  acids  (oleic  acid,
linoleic acid ) by mechanical agitation of evaporated films in the presence of buffer solutions.
Used for ligand mediated drug targeting.
CRYPTOSOMES:
Lipid vesicles with a surface coat composed of PC and of suitable polyoxyethylene
derivative of phosphatidylethanolamine. Used for ligand mediated drug targeting.
EMULSOMES:
Nanosize lipid particles (bioadhesive nano emulsion) consisted of microscopic lipid
assembly with apolar core which contains water insoluble drugs in the solution form without
requiring any surface active agent or co solvent. These fat cored lipid paticles are dispersed in
an  aqueous phase.  [13] Emulsome represents  lipid  based  drug delivery systems with wide
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range  of  therapeutic  applications  especially  for  parenteral  delivery  poorly  water  soluble
drugs.
                                 
Figure 3: Diagrammatic structure of emulsome
DISCOMES:
Niosomes solubilised with non-ionic surfactant solution (Polyoxyethylene cetyl ether
class, Solulan C24). Discomes are large (12-60µm) structures and are capable of entrapping
water-soluble solutes. [2] Used for ligand mediated drug targeting.
AQUASOMES:
Three  layered  self-assembly  compositions  with  ceramic  carbon  nanocrystalline
particulate  core  coated  with  glassy  cellobiose.  Used  for  specific  targeting,  molecular
shielding.
ETHOSOMES:
Ethosomes are lipid “soft, malleable vesicles” embodying a permeation enhancer and
composed of phospholipid, ethanol and water. Used for targeted delivery to deep skin layers.
GENOSOMES:
Artificial macromolecular complexes for functional gene transfer, cationic lipids are
most suitable because they possess high biodegradability and stability in the blood stream.
Used for cell specific gene transfer.
PHOTOSOMES:
Photolyase encapsulated in liposomes, which release the contents, by photo-trigerred
charges in membrane permeability characteristics. Used for photo dynamic therapy.
ERYTHROSOMES:
Page No: 15
Chapter II                                                      Vesicular Systems - Review
Red blood cells  offer a number of possibilities as  drug carriers in controlled drug
delivery systems. The release rate from erythrosomes, longevity and physical characteristics
can be easily manipulated to alter the delivery mechanism and are used in both site-directed
and sustained-release systems [9]. Liposomal systems in which chemically crosslinked human
erythrocytes, cytoskeletons are used as a support to which lipid bilayer is coated. Used for
effective  targeting  macromolecular  drugs.  An  erythrocyte  based  drug  carrier,
‘Nanoerythrosome,’ has been developed by extrusion of erythrocyte ghosts to produce small
vesicles  having  an  average  diameter  of  100  nm. Artificial  red  blood  cells  prepared  by
encapsulating haemoglobin by interfacial polymerization have been used as oxygen carriers. 
HEMOSOMES:
Haemoglobin containing liposomes engineered by immobilizing haemoglobin with a
polymerisable phospholipids. Used for high capacity oxygen carrying system.
PROTEOSOMES:
 High molecular weight multi-subunit enzyme complexes with catalytic activity, which
is  specifically due to  the  assembly pattern of  enzymes.  Used for  better  catalytic  activity
turnover than non-associated enzymes.
VESOSOMES:
Nested bilayer compartments in vitro via the “interdigitated” bilayer phase formed by
adding ethanol to a variety of saturated phospholipids. Application: Multiple compartments of
the vesosome give better protection to the interior contents in serum.
ARCHAEOSOMES:
Vesicles composed of glycerolipids of archaea with potent adjuvant activity. 
APSASOMES: [11]
Ascorbyl palmitate vesicles-Aspasomes. 
Ascorbyl palmitate (ASP) was explored as bilayer vesicle forming material. Vesicles
prepared  with  amphiphiles  having  antioxidant  property  may  have  potential  applications
towards disorders implicated with reactive oxygen species. Ascorbic acid (vitamin-C) is a
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major antioxidant in human plasma as well as in and across cell membranes. It reduces α-
tocopherol as well as peroxides and reactive oxygen species such as superoxide.
COLLOIDOSOMES: [8]
 Colloidosomes is a novel class of microcapsules whose shell consists of coagulated
or fused colloid particles at interface of emulsion droplets. The particles self assemble on the
surface of droplets in order to minimize the total interfacial energy forming colloidosomes.
Colloidosomes are the spherical  capsules  fabricated  from the controlled  self  assembly of
colloidal particles onto the emulsion droplets. For these colloidosomes, colloidal particles in
aqueous solution adsorb onto the emulsion droplets in order to minimize the total interfacial
energy and act as bridge between particles, locking them together and stabilizing the structure
to allow removal of initial templating interfaces.
CUBASOMES: [12]
Cubosomes consist  of honeycombed (cavernous) structures separating two internal
aqueous  channels  and  a  large  interfacial  area.  Self-assembled  cubosomes  as  active  drug
delivery systems and they exhibit  different  internal  cubic structure and composition with
different drug-loading modalities. Cubosomes are nanoparticles whose size ranges from 10-
500nm in diameter  they appear like dots square shaped, slightly spherical.
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CHAPTER – III
NIOSOMES – REVIEW.
Niosomes  are  vesicles  consisting  of  non-ionic  surfactants.  Niosomes  were  first
reported by Vanler-berghe et al. (1972) and later by Handjani-Vila et al (1979) for their use
in cosmetic industry  [14].  Niosomes (Non- ionic surfactant vesicles- NSV) are now widely
studied as alternative to liposomes (Baillie et al., 1985) [5].  From early 1980s, niosomes have
gained wide attention by researchers for their use as drug targeting agents and drug carriers
while avoiding demerits associated with the conventional form of drugs. These NSVs are
widely used not only as models for cell membranes but also as drug carriers to deliver the
drug into the targets of tumours and viruses.
                 Niosomes are essentially non-ionic surfactant based multilamellar or unilamellar
vesicles in which an aqueous solution is entirely enclosed by a membrane resulted from the
organization of surfactant macromolecules as bilayers [5]. Niosomes or Non- ionic surfactant
vesicles are microscopic lamellar structures formed on admixture of non-ionic surfactant of
alkyl or dialkyl polyglycerol ether class and cholesterol with subsequent hydration in aqueous
media.  The  large  number  of  available  vesicle  forming non-ionic  surfactants  makes  these
niosomes more attractive than liposomes for industrial production both in pharmaceutical and
cosmetic applications.
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a) 2-dimension
                                  
b) 3-dimension
                         
Figure 4: Structure of Niosomal vesicle a) in 2D (A=span, B=cholesterol, C=dicetyl
phosphate).
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I. NATURE OF NIOSOMAL BILAYER [5, 7]
         The bilayer membrane is an ordered structure and may exist in the gel state (or)
liquid crystalline state. The gel state being most ordered structure and the liquid crystal state
being less ordered. Addition of cholesterol abolishes the gel liquid transition state and makes
the vesicle as in gel state (or) less leaky. So the nature of bilayer state depends on the type of
lipid (or) surfactant and cholesterol.
II. VESICULAR COMPOSITION [7, 17]
Niosome consists of 2 components, which are the main component and membrane
additives.  The  compositions  of  the  main  component  are  mainly  non-ionic  surfactants.
Membrane additives are substances that are added in the formulation in order to stabilize   the
niosomes. 
1. Main component : Non-ionic surfactant 
2. Membrane additives: 
• Cholesterol                        
• Stabilizer- Charged molecule
3. Drug        
  
1. NON- IONIC SURFACTANTS [7]
              Non-ionic  surfactants  are  uncharged  amphiphilic  compounds.
Like lipids  the non-ionic surfactants also orient  in an aqueous medium as  planar  bilayer
lattices wherein polar (or) hydrophilic heads align facing aqueous bulk while hydrocarbon
segments are so aligned that their interaction with aqueous media is minimized.
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                   Every bilayer folds over itself to be a continuous membrane that forms vesicles so
that hydrocarbon / water interface remains no more exposed.
Examples of non-ionic surfactants forming vesicles are,  Polyoxy ethylene fatty acid
esters, Polyoxy ethylene alkyl esters (including ethers of fatty alcohols) Polyoxy ethylene
sorbitan  esters,  Polyoxy ethylene  glyceryl  mono  and  diesters,  sucrose  diester,  Propylene
glycol stearate, Long chain acyl amide, C12-C22 fatty alcohols etc.,
          BRIJTM (Polyoxy ethylene fatty acid esters), SPANTM(Sorbitan fatty acid esters)
and TWEENTM (Polyoxy ethylene derivatives of sorbitan fatty acid esters.) are commercially
available amphiphile surfactants. 
                         The choice of non-ionic surfactant on vesicle formation depends on
hydrophilic  lipophilic  balance  (HLB),  critical  micellar  concentration  (CMC)  and  critical
packing parameter of amphiphiles.
HLB of surfactants [15]
Hydrophilic lipophilic balance (HLB) is a good indicator of the vesicle forming
ability of Surfactants.
 With the sorbitan ester (span) surfactants, a HLB number of between 4 and 8 was
found to be compatible with vesicles formation.
 Tween 20 having HLB number 16.7 is to be too hydrophilic to form a bilayer
membrane. However with an optimum level of cholesterol it forms niosomes.
 In addition to this ether amphiphiles bearing a steroidal C14 alkyl (or) C16 alkyl
groups form vesicles.
 Polyoxy  ethylene  alkyl  ether  (Brij)  forming  vesicles  increase  six-fold
bioavailability for (all surfactants that had HLB values from 8-14) intranasally
administered   insulin.
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 Low phase transition temperature, increased leakage of low MW drugs from the
aqueous compartment and decreased stability of the niosomes are the vesicular
properties of hydrophilic surfactants.
 High phase transition temperature, decreased leakage of low MW drugs from the
aqueous compartment and increased stability of the niosomes are the vesicular
properties of hydrophobic surfactants.
CMC OF THE SURFACTANTS [15]
      The CMC of the surfactants is the amount of free surfactant resulted that the
presence of micelles does not influence the toxicity and the amount of free surfactant in the
vesicle suspension is not primarily responsible for the toxic effects of the formulation.
CRITICAL PACKING PARAMETER [5, 15, 16]
    The micelle-forming amphiphiles show relatively high solubility in water. The
concentration corresponds to CMC in case of membrane forming lipids is significantly low.
Unfortunately, the prediction of vesicle formation characteristics is not just a matter of HLB
numbers, CMC values, it involves several other factors.  Israelachvili  (1991) suggested that
parameters of self assemblages are governed by critical packing parameter (CPP). Their self-
organization in water is mainly the result of the hydrophobic effect, as in the case of soap and
detergent  however  it  also  depends  on  the  relative  proportions  of  hydrophobicity  and
hydrophilicity of the lipids as well as mesogen molecular geometry. The symmetry of the
lipid self-assembly and liquid crystalline-phase formation show strong dependence on the
molecular shape of the mesogen/amphiphiles. The different shapes and volumes constructing
different phases are characterized by a dimensionless CPP. 
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The critical packing parameter (CPP) is defined as
 CPP = v / lc.ao
Where, 
v    =   Hydrophobic group volume.
lc = The critical hydrophobic group length
ao = The area of hydrophilic head group
                  Figure 5: Schematic representation of an amphiphile. 
 The vesicle forming ability of amphiphiles depends on the CPP value which is determined by
using hydrophobic group volume and area of hydrophilic head group.
CPP = 0.5-1 -- Surfactant is likely to form vesicles.
CPP < 0.5   -- Large hydrophilic head group give spherical micelles.
CPP >  0.5  --  Large  contribution  from  the  hydrophobic  group  value  produces
inverted   micelles.
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 The different structures formed by amphiphilic molecules are represented in figure: 6.
Figure 6: Examples of structures formed by amphiphilic molecules.
2. CHOLESTEROL [5, 16, 17]
     Steroids are important components of cell membrane bring bilayer fluidity and
permeability. The most common additive found in niosomal systems is cholesterol which is
known to  abolish  the  gel  to  liquid  phase  transition of  liposomal  and niosomal  systems,
resulting  in  less  leakiness  of  the  vesicles.  However,  it  may  have  effects  on  membrane
permeability,  encapsulation efficiency,  bilayer rigidity,  ease of rehydration of freeze dried
niosomes  and  toxicity.  In  general,  it  has  been  found  that  a  molar  ratio  of  1:1  between
cholesterol and non-ionic surfactants is an optimal ratio for the formulation of physically
stable niosomal vesicles Cholesterol can be incorporated in bilayers at significantly higher
molar ratio, however by itself does not form niosomal bilayer. Its -OH group orients towards
aqueous phase while aliphatic chains parallel to the hydrocarbon chain of surfactants.
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Cholesterol is known to have important modulatory effect on the bilayer membrane.
Cholesterol  acts  as  ‘fluidity  buffer’,  since below the phase transition it  tend to  make the
membrane less ordered while  above the transition it  tends  to make the membrane more
ordered, thus suppressing the tilts and shift in membrane structure specifically at the phase
transition.
Role of cholesterol in bilayer formation:
• Acts as a fluidity buffer.
• After intercalation with phospholipid molecules alters the freedom of motion
of carbon molecules in the acyl chain.
• Restricts the transformations of trans- to gauche- conformations.
3. DRUG [16]
              The drug is actively or passively entrapped in vesicles. In passive trapping, drug and
lipids are co dispersed with fraction of drug being entrapped, according to hydrophobicity
and electrostatic charge. If the drug is hydrophilic, it will be entrapped in the internal aqueous
phase and the hydrophobic drug will be entrapped in lipid region. Active trapping can be
achieved  by  ion  gradients  placed  across  the  niosomal  membranes.  This  allows  drug
entrapment after the niosomal carrier has been formulated.
The physico-chemical properties of encapsulated drug influence charge and rigidity of
the niosome bilayer. The drug interacts with surfactant head groups and develops the charge
that creates mutual repulsion between surfactant bilayers and hence increases vesicle size.
The aggregation of vesicles is prevented due to the charge development on bilayer.
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4. STABILIZER [5, 16, 27]
           One of the methods used to stabilize niosomes is to add a charged molecule to the
bilayer. Used for preventing aggregation of niosomes. [17] 
• Negatively charged molecules - Dicetylphosphate (DCP),
- Phosphatidic acid.
• Positively charged molecules - Stearylamine (STR), 
-Cetylpyridinium chloride.
• Non-ionic substances - Cholesteryl poly-24-oxyethylene ether (SC24)
Normally, the charged molecule is added in niosomal formulation in an amount of
2.5–5 mol% because the high concentration of charged molecules can inhibit the formation of
niosomes. It is added in niosomal Stable niosomal dispersion must exhibit a constant particle
size and a constant level of entrapped drug. There must be no precipitation of the membrane
components. 
         The inclusion of a charged molecule in the bilayer shifts the electrophoretic mobility
making it positive or negative and prevents niosomes aggregation.
Examples of positive charge inducers (11, 12)
Protamine, Polyamine, Polyvinyl pyridine, Poly oxethane, Poly amidoamines, Cetyl
pyridinium chloride, Stearyl amine, Diethanolamine etc.,
 Examples of negative charge inducers (11, 12)
Oleic  acid,  Palmitic  acid,  Dicetyl  phosphate,  Cetyl  sulphate,  Phosphatidic  acid,
Phosphatidyl serine etc,
The amount of charge modifying compound ranges from 0.01 to 0.5-wt%
 
III. TYPES OF NIOSOMES [7]
           They are divided in to three types 
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             They are as follows,
1. Multilamellar niosomes (>0.05µm)  
2. Small unilamellar niosomes (0.025-0.05µm)
3. Large unilamellar niosomes (>0.01µm)
Figure 7: Schematic illustration of different size and number of lamellae 
SUV: Small unilamellar vesicles LUV: Large unilamellar vesicles
 MLV: Multilamellar vesicles, MVV: Multi vesicular vesicles.
IV.METHODS OF PREPARATION OF NIOSOMES [5, 7, 15, 18,19, 10, 11, 12, 13, 17, 18, 19, 20, 21]
1. Ether Injection Method
2. Hand Shaking Method (Thin film hydration technique)
3. Sonication
4. Microfludization
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5. Multiple Membrane Extrusion method
6. Reverse Phase Evaporation Technique (REV)
7. Trans membrane pH gradient (inside acidic) Drug Uptake Process (remote
Loading
8. The “Bubble” Method
9. Ethanol injection method
10. Formation of niosomes from proniosomes
11. Emulsion method
12. Lipid injection method
13. Niosome preparation using micelle
1. Ether Injection Method [5, 15, 18, 19]
          This method provides a meaning of making niosomes by slowly injecting the
surfactant/cholesterol mixture (dissolved in diethyl ether)  in to the aqueous phase maintained
at 600 through 14-gauge needle.  This method produces  unilamellar  vesicle  shows highest
entrapment  efficiency.  Depending upon the  conditions  used,  the  diameter  of  the  vesicles
range from 50-1000nm.
2. Hand Shaking Method (Thin film hydration technique) [5, 15, 18,22]
               The mixture of vesicles forming ingredients like surfactant and cholesterol
are dissolved in a volatile organic solvent (diethyl ether, chloroform or methanol) in round
bottom flak.  The solvent is evaporated at a temperature (200C) using a rotary evaporator,
leaving a thin layer of solid mixture deposited on the wall of the flask. The dried surfactant
film can be rehydrated with aqueous phase maintained at 0-60º C with gentle agitation. 
The apparatus used for thin film hydration method and the mechanism of formation of
niosomes is shown in the Figure.8a & 8b. 
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Figure-8a: Rotary Flash Evaporator.
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                       Figure 8b: Possible formation of niosome vesicles when hydrating in 
aqueous solution. [5, 33] 
Mechanism of Niosome Formation:
The lipids are casted as stacks of film from their organic solution using rotary flash
evaporator  under  reduced  pressure.  And then  the  casted  film is  dispersed  in  an  aqueous
medium upon hydration the lipids (surfactants and cholesterol)  swell and peel off  from the
wall of the round bottom flask and vesiculate forming multilamellar vesicles. The mechanical
energy required for the swelling of the lipids and dispersion of casted lipid film is imparted
by manual agitation. 
Thermo sensitive niosomes are prepared at 60º C by evaporating organic solvent and
leaving a thin film of lipid of on the wall  of rotary flask evaporator.  The aqueous phase
containing drug is added slowly by shaking at room temperature followed by sonication.
3. Sonication [14, 22, 34, 35]
                The surfactant/cholesterol mixture in organic solvent is mixed with aqueous
phase in a vial. Then the mixture is probe or bath sonicated at 600 for 3minutes to produce
niosomes. The vesicles produced are unilamellar and smallest in size.
4. Micro fludization [18, 22, 35]
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                    Microfludization is the recent technique used to prepare unilamellar vesicles of a
defined size  distribution.  This  method is  based  on submerged jet  principle in  which two
fluidized streams interact at ultra high velocities (up to 1700 ft/sec) in precisely defined micro
channels  within  the  interaction  chamber.  The  impingement  of  thin  liquid  sheet  along  a
common front is arranged such that the energy supplied to the system remains within the area
of  niosomes  formation.  The  result  is  a  greater  uniformity,  smaller  size  and  better
reproducibility of niosomes formed (Mayer et al., 1985).
 5. Multiple Membrane Extrusion method [18, 22] 
        Mixture of surfactant, cholesterol and dicetyl phosphate in chloroform is made into thin
film  by evaporation.  The  film  is  hydrated  with  aqueous  drug  solution  and  the  resultant
suspension is extruded through polycarbonate membranes which are placed in series up to 8
passages. It is a good method for controlling niosomes size. (Mayer et al., 1985).
6. Reverse Phase Evaporation Technique (REV) [18, 21, 22]
                      The novel key in this method is the removal of solvent from an emulsion by
evaporation.  Cholesterol  and  surfactant  (1:1)  are  dissolved  in  a  mixture  of  ether  and
chloroform. An aqueous phase containing drug is added to this and the resulting two phase
system is sonicated at 4-5°C. The clear gel formed is further sonicated after the addition of a
small amount of phosphate buffered saline (PBS).  The organic phase is removed at 40°C
under low pressure. The resulting viscous niosome suspension is diluted with PBS and heated
on a water bath at 60°C for 10 minutes to yield niosomes. 
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7.  Trans  membrane  pH  gradient  (inside  acidic)  Drug  Uptake  Process
(remote Loading) [18, 22, 35]
                       Surfactant and cholesterol are dissolved in chloroform. The solvent is then
evaporated under reduced pressure to get a thin film on the wall of the round bottom flask.
The film is  hydrated with 300 mM citric  acid (pH 4.0)  by vortex  mixing.  The resulting
multilamellar  vesicles are then treated to  three freeze thaw cycles  and sonicated.  To this
niosomal suspension, aqueous solutions containing 10 mg/ml of drug is added and vortexed.
The pH of the sample is then raised to 7.0-7.2 with the addition of 1M disodium phosphate
(this causes the drug which is outside the vesicle to become non-ionic and can then cross the
niosomal  membrane,  and once  inside it  is  again  ionized thus  not  allowing it  to  exit  the
vesicle). This mixture is later heated at 60°C for 10 minutes to give niosomes. 
8. The “Bubble” Method [18, 22, 35]
                     It is novel technique for the preparation of liposomes and niosomes without the
use of organic solvents. The bubbling unit consists of round-bottomed flask with three necks
positioned in water bath to control the temperature. Water-cooled reflux and thermometer is
positioned  in  the  first  and  second  neck  and  nitrogen  supply  through  the  third  neck.
Cholesterol  and  surfactant  are  dispersed  together  in  this  buffer  (pH  7.4)  at  70°C,  the
dispersion mixed for 15 seconds with high shear homogenizer and immediately afterwards
“bubbled” at 70°C using nitrogen gas. 
9. Ethanol injection method [21]
This method has been reported as one of the alternatives used for the preparation of
small unilamellar vesicles (SUVs) without sonication. In this method, an ethanol solution of
surfactant is injected rapidly through a fine needle into excess of saline or other aqueous
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medium. Vaporization of ethanol leads  to the formation of vesicles.  Fang et al  entrapped
enoxacin in niosomes using this particular method. [22]
10. Formation of niosomes from proniosomes [5, 18, 22, 29, 30, 31]
                          Another method of producing niosomes is to coat a water-soluble carrier such
as sorbitol with surfactant.  The result of the coating process is a dry formulation. In which
each water-soluble particle is  covered with a thin film of dry surfactant.  This preparation
termed as “proniosomes”. The niosomes are recognized by the addition of aqueous phase as
T > Tm and brief agitation. 
T – Temperature
Tm – Mean phase transition temperature
      
        
Blazek-Walsh A.I.  et  al  [20] have reported the formulation of  niosomes from maltodextrin
based proniosomes. This  provides  rapid reconstitution of niosomes with minimal residual
carrier. Slurry of maltodextrin and surfactant was dried to form a free flowing powder, which
could be rehydrated by addition of warm water. 
11.  Emulsion method [20]
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The  oil  in  water  emulsion  is  prepared  from  an  organic  solution  of  surfactant,
cholesterol, and an aqueous solution of the drug. The organic solvent is then evaporated,
leaving niosomes dispersed in the aqueous phase.
12. Lipid injection method [20]
This method does not require expensive organic phase. Here, the mixture of lipids and
surfactant  is  first  melted  and  then  injected  into  a  highly agitated,  heated  aqueous  phase
containing dissolved drug. Here, the drug can be dissolved in molten lipid and the mixture
will be injected into agitated, heated aqueous phase containing surfactant.
13. Niosome preparation using micelle [9]
Niosomes may also be formed from a mixed micellar solution by the use of enzymes.
A  mixed  micellar  solution  of  C16G2,  dicalcium  hydrogen  phosphate,  polyoxyethylene
cholesteryl sebacetate diester (PCSD) converts to a niosome dispersion when incubated with
esterases.  PCSD  is  cleaved  by  the  esterases  to  yield  polyoxyethylene,  sebacic  acid  and
cholesterol. Cholesterol in combination with C16G2 and DCP then yields C16G2 niosomes.
V. THE REDUCTION OF NIOSOME SIZE [5]
A reduction in vesicle size may be achieved by a number of 
 Probe sonication
 Extrusion through 100nm nucleopore filter
 The combination of sonication and filtration
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 Micro fluidizer
 High pressure homogenizer.
VI. SEPERATION OF UNENTRAPPED DRUG [15, 18, 27] 
                       In vesicular system half of the drug is encapsulated and half is external to the
niosomes may eventually yielding systems with a beneficial biphasic biodistribution profile.
The  removal  of  unentrapped  solute  from  the  vesicles  can  be  accomplished  by  various
techniques, which include: - 
1. Dialysis 
The aqueous niosomal dispersion is dialyzed in dialysis tubing against phosphate buffer or
normal saline or glucose solution. 
2. Gel Filtration 
                The unentrapped drug is removed by gel filtration of niosomal dispersion through a
Sephadex-G-50 column and elution with phosphate buffered saline or normal saline. 
3. Centrifugation  
               The niosomal suspension is centrifuged and the supernatant is separated. The pellet
is washed and then resuspended to obtain a niosomal suspension free from unentrapped drug. 
VII. CHARACTERIZATION OF NIOSOMES [7, 20, 21]
1. Entrapment efficiency
                  After preparing niosomal dispersion, unentrapped drug is separated by dialysis,
centrifugation  or  gel  filtration as  described  above  and  the  drug  remained  entrapped  in
niosomes is determined by complete vesicle disruption using 50% n-propanol or 0.1% Triton
X-100 and analyzing the resultant solution by appropriate assay method for the drug. Where,
(Total drug – Drug in supernatant) 
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  % drug entrapment =                   × 100.
                                                                 Total drug
2. Vesicle diameter
                      Niosomes, similar to liposomes, assume spherical shape and so their diameter
can  be  determined  using  light  microscopy,  photon  correlation  microscopy,  and  Scanning
electron microscopy and freeze fracture electron microscopy. 
3. In-vitro release
                   A method of in-vitro release rate study includes the use of dialysis tubing. A
dialysis sac is washed and soaked in distilled water. The vesicle suspension is pipetted into a
bag made up of the tubing and sealed. The bag containing the vesicles is placed in 200 ml of
buffer solution in a 250 ml beaker with constant shaking at 25°C or 37°C. At various time
intervals, the buffer is analyzed for the drug content by an appropriate assay method.
VIII. FACTORS AFFECTING VESICLES SIZE, ENTRAPMENT EFFICIENCY AND
RELEASE CHARACTERISTICS (7, 9, 11]
1. Drug
             Entrapment of drug in niosomes increases vesicle size, probably by interaction of
solute  with  surfactant  head  groups  and  mutual  repulsion  of  the  surfactant  bilayers.  The
hydrophilic lipophilic balance of the drug also affects degree of entrapment. 
2.  Amount and type of surfactant
                The mean size of niosomes increases proportionally with increase in the HLB of
surfactants like Span 85 (HLB 1.8) to Span 20 (HLB 8.6) because the surface free energy
decreases with an increase in hydrophobicity of surfactant.
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3.   Cholesterol content and charge
                  Inclusion of cholesterol in niosomes increases its hydrodynamic diameter and
entrapment efficiency. An increase in cholesterol content of the bilayers resulted in a decrease
in the release rate of encapsulated material and therefore an increase of the rigidity of the
bilayers obtained.
               Presence of charge tends to increase the interlamellar distance between successive
bilayers in multilamellar vesicle structure and leads to greater overall entrapped volume. 
4.  Methods of preparation
               Hand shaking method forms vesicles with greater diameter (0.35-1µm)  compared to
the ether injection method (50-1000nm). Small sized niosomes can be produced by Reverse
Phase  Evaporation (REV) method.  Microfludization method gives  greater  uniformity and
small size vesicles. 
                Parthasarthi  et al prepared niosomes by transmembrane pH gradient (inside
acidic) drug uptake process. Niosomes obtained by this method showed greater entrapment
efficiency and better retention of drug
 5.   Resistance to osmotic stress
              Addition of a hypertonic salt solution to a suspension of niosomes brings about
reduction in  diameter.  In  hypotonic  salt  solution,  there  is  initial  slow release with  slight
swelling of vesicles probably due to inhibition of eluting fluid from vesicles followed by
faster release which may be due to mechanical loosening of vesicles structure under osmotic
stress. 
IX. ROUTES OF ADMINISTRATION[5]
        Azmin et al., investigated niosomal delivery of methotrexate to mice by oral and
intravenous  administration.  On  oral  administration  absorption  of  methotrexate  was
significantly increased. 
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               Hofland et al., studied transdermal delivery of estradiol entrapped within niosomes.
Brewer and Alexander performed studies on adjuvant activity of niosomes on the BALB/C
humoral  response  to  bovine  serum  albumin  after  intraperitoneal  and  subcutaneous
administration.
X.IN VIVO BEHAVIOUR OF NIOSOMES [5]
              In vivo niosomes have been found equiactive in liposomes in improving the
therapeutic performance of drug  and their distribution in the body .Like liposomes, niosomes
are  taken  up  by  the  liver  and  break  down  to  release  the  free  drug  which  re  enters  the
circulation and maintains the plasma drug level.
              Parthasarathi et al found niosomes to be stable in plasma.  Moser et al found
niosomes bearing hemoglobin to be physically stable and albumin, transferrin were absorbed
on vesicles without destabilizing them.
XI. CHARACTERIZATION OF NIOSOMES: [14, 21, 34]
Table no 1: Analytical methods for characterizing niosomes.
S.NO. PARAMETER(S) METHOD(S)
1.
Morphology
Transmisson Electron Microscopy, Scanning
Electron Microscopy, Optical Microscopy(OM),
Cryo- Scanning Electron Microscopy, Freeze
Fracture Microscopy.
2. Vesicle size determination
and Size distribution 
Dynamic Light Scattering using particle Size
Analyzer(PSA), Malvern Master Sizer, Photon
Correlation Spectroscopy (PCS), OM, SEM,
Laser Diffraction PSA.
Page No: 41
Chapter - III                                                                Niosomes - Review
3. Zeta potential/ Surface
Charge
Micro-electrophoresis meter, High Performance
Capillary electrophoresis and Malvern Zeta Sizer
(Zetameter)
4. Rheological Properties
(Elasticity)
Ostwalt U-tube, Low shear Rheo Analyzer &
Extrusion method.
5. Micro viscosity of niosomal
membrane
Spectroflurophotometer.
6. Viscosity Ostwald’s viscometer
7. Membrane micro-structure Negative Staining TEM.
8. Lamellarity OM, TEM
9. Bilayer spacing and thickness X-Ray Scattering Analysis.
10. Gel-Liquid transition
temperature & Thermal
Analysis
Differential Scanning calorimetry, Differential
Thermal Analysis, & Hot Stage Microscopy.
11. Circular Dichroism Spectropolarimeter.
12. Micropolarity measurement Fluorescence Spectrophotometer.
13. Fluidity of vesicles Differential Polarized Phase Fluorimetry
14. Turbidity measurement UV-Visible Diode Array Spectrophotometer.
15. Entrapment Efficiency Centrifugation method, Dialysis method, Gel
Exclusion Chromatography.
16. In-vitro release rate Using dialysis membrane.
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17. Permeation study Franz Diffusion Cell.
18. Conductivity Conductometer
XII.TOXICITY AND STABILITY [5]
                Non-ionic surfactants used in niosomes are non-toxic and no toxic effects have
been reported so far in animal studies due to the use of niosomes as drug carriers.
            Jain et al didn’t observe any morphological changes on storage for three months.
Baille et al determined the stability in buffer and reported that the amount of entrapped solute
would be retained under long term storage conditions.
XIII. ADVANTAGES OF NIOSOMES [22, 24, 27, 28] 
 Biodegradable, biocompatible and non-immunogenic.
 Can entrap a wide range of compounds ranging from small soluble ions to complex
macromolecules.
 They possess a great deal of flexibility in their structural characteristics.
 Niosomes can entrap both water-soluble and oil soluble drugs.
 They can be made to reach the site of action by oral, parenteral and as well as by
topical route.
 Enhance the skin penetration of drugs.
 Prolong the circulation of entrapped drugs.
 Due to the presence of better  targeting nature it  is  proved that  usage of  niosomal
technology in treating cancer, parasitic, viral and other microbial diseases are more
effective.
 Reduces systemic toxicity of drugs such as anti-cancer, anti-infective etc.,
Page No: 43
Chapter - III                                                                Niosomes - Review
 As a carrier for drug delivery to specific cells, they improve the therapeutic index of
drug by restricting its effects to target cells.
XIV.STUDIES ON NIOSOMES AND THEIR MEDICINAL APPLICATIONS [14, 34]
Table no: 2.
S.NO. PURPOSE / APPLICATION DRUGS STUDIED
1. Cancer chemotherapy and
targeted drug delivery
Doxorubicin, Danorubicin Hcl, Methotrexate
(MTX), 5-flurouracil, Adiramycin,
Vincristine, Cytarabine Hcl
2. Transdermal drug delivery Nimesulide, Lidocaine, Cyclosporine,
Estradiol, Erythromycin, α-interferon,
Indomethacin, Enoxacin, Finasteride.
3. Enhancement of bioavailability Diclofenac, Flurbiprofen, Bleomycin,
Vincristine, Doxorubicin, Acetazolamide.
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4. Ocular drug delivery Timolol maleate, Acetazolamide,
Cyclopetolate.
5. Pulmonary drug delivery All trans retinoic acid (ATRA).
6. Brain Targeted Drug Delivery VIP loaded glucose bearing niosomes.
7. Protein/Peptide and Hormone
delivery
LHRH, Insulin (oral), 9-desglycinamide
-8-arginine vasopressin (DGAVP).
8. Local/Intra Articular drug
delivery
Radiolabelled Diclofenac Na niosomal
vesicles.
9. Enhancement of stability
improved photostability
DGAVP, Haemoglobin, Dithranol,
β-carotene
10. Improved thermal and
oxidative stability
β-carotene
11. Prolonged release Propranolol Hcl, Doxorubicin.
12. For improved anti-infective
therapy
Sodium stibogluconate, Rifampicin.
13. Immuno stimulatory niosomes
(antigenic)
Haemagglutinin, Ovalbumin, Hepatitis B
DNA vaccine niosomes, Plasmid DNA
encoding proteins of Hepatitis B virus,
Influenza DNA vaccine niosomes, and
Tetanus Toxoid Niosomes.
14. Diagnosis Urokinase
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15. Radio-pharmaceutical carrier
and imaging study.
Iobitridol (X-ray imaging studies), and
Iopromide (Kidney imaging studies)
OTHER APPLICATIONS
(a) Sustained release
Niosomes can provide relatively constant and sustained blood stream level of
drug concentration. Sustained release action of niosomes could be applied to drugs with low
therapeutic  index  since  these  could  be  maintained  in  the  circulation  via  niosomal
encapsulation.
(b) Localized drug action
Localization of drug action results in enhancement of efficacy or potency of
the drug and at the same time reduces its systemic toxic effects. Niosomes are a promising
vehicle for drug delivery and being non-ionic it is less toxic and improves the therapeutic
index of drug by restricting its action to target cells.
ENHANCEMENT OF BIOAVAILABILITY (LIPOPHILICITY) [2]
                           The lipophilic form of drug has enhanced membrane/water partition
coefficient as compared to the hydrophilic form of the drug. A big advantage of increased
bioavailability through increased lipophilicity is reduction in drug dosage.                     
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CHAPTER – IV
LITERATURE REVIEW.
1. Mahmoud Mokhtar  et a1., studied the effect of some formulation parameters on
flurbiprofen  encapsulation  and  release  rates  of  niosomes  prepared  from  proniosomes.
Proniosomal gels or solutions of flurbiprofen were developed based on span 20 , span 40,
span 60, and span 80 without and with  cholesterol.  Niosomes formed immediately upon
hydrating proniosomal formulae. The   entrapment efficiency (EE%) of flurbiprofen (a poorly
soluble drug) was either determined by exhaustive dialysis of freshly prepared niosomes or
centrifugation  of  freeze-thawed  vesicles.  The  influence  of  different  processing  and
formulation variables such as surfactant chain length, cholesterol content, drug concentration,
total lipid concentration, negatively or positively charging lipids, and the pH of the dispersion
medium on flurbiprofen EE% was demonstrated. Results indicated that the EE% followed the
trend  Sp  60  (C18)>Sp  40  (C16)>Sp  20  (C12)>Sp  80  (C18).  Cholesterol  increased  or
decreased the EE% depending on either the type of the surfactant or its concentration within
the formulae.
2. Toshimitsu  Yoshioka  et  al.,  studied the  formation  of  niosomes  with  a  series  of
sorbitan monoesters  (Span 20, 40,  60 and 80) and a sorbitan trioleate (Span 85) using a
mechanical shaking technique without sonication. 5(6)-Carboxyfhxxescein (CFI was used as
a model solute to investigate entrapment efficiency and release. For Span 80, cholesterol and
dicetyl phosphate DCP) in the molar ratio 47.5: 47.5: 5.0, entrapment efficiency increased
linearly  with  increasing  concentration  of  lipid.  Entrapment  efficiency  increased  with
increasing cholesterol content when vesicles were prepared by changing the molar ratio of
non-ionic surfactant to cholesterol. Most efficient entrapment of CF occurred with Span 60
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(HLB  4.7).  Mean  size  of  the  un-sonicated  niosomes  showed  a  regular  increase  with
increasing HLB from Span 85 (HLB 1.8) to Span 20 (HLB 8.6). The release rate of CF from
vesicles depended on the surfactant used in the preparation of the vesicles.
3. Behrooz Nasseri et al., explained the effect of cholesterol and temperature on the
elastic  properties  of  niosomal  membranes.  The  mechanical  characteristics  of  non-ionic
bilayer membranes composed of span 60, cholesterol and poly-24- oxyethylene cholesteryl
were studied by measuring the modulus of surface elasticity (µ), a measure of membrane
strength,  as  a  function  of  cholesterol  content  and  temperature.  The  modulus  of  surface
elasticity increased slowly with increasing cholesterol concentration, with a sharp increase
around  40  mol%  cholesterol  and  displayed  a  maximum  around  47.5  mol%  cholesterol.
Further cholesterol resulted in a decrease in µ. Generally, the interaction of cholesterol with
the span 60 should increase the rigidity of the membrane. However, the latter effect may be
due to the formation of cholesterol clusters at high cholesterol content where excess amounts
of cholesterol cannot interact with the sorbitan monostearate, and deposits on the bilayers
compromising their uniformity, strength and permeability. 
4. Aranya Manosroi et al., studied the vesicles prepared with hydrated mixture of 
various non-ionic surfactants and cholesterol. The bilayer formation was characterized by X-
cross formation under light polarization microscope. Membrane rigidity was measured by 
means of mobility of fluorescence probe as a function of temperatures. The stearyl chain 
(C18) non-ionic surfactant vesicles showed higher entrapment efficiency than the lauryl chain
(C12) non-ionic surfactant vesicles. Cholesterol was used to complete the hydrophobic 
moiety of single alkyl chain non-ionic surfactants for vesicle formation. 
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5. Wei Hua et al.,  prepared highly stable innocuous niosome composed of only three 
components in Span 80/PEG 400/H2O system. The niosome properties are studied by some 
means of freeze fracture replication-transmission electron microscopy, negative staining-
transmission electron microscopy, dynamic light scattering and differential scanning 
calorimetry. The obtained results indicate that the niosome can be stable for over one year. 
The niosome diameter is between 100 and 180 nm. The compositions of the system affect the 
preparation and properties of the niosome.
6. Prasun Bandyopadhyay et al., studied of the self-organization of nonionic surfactant
span 60 in presence of fatty alcohol (stearyl, cetyl and lauryl) is presented. When ethanolic
solution of the surfactant–fatty alcohol (1:1) mixture is added in water spontaneous large
unilamellar  vesicles  (LUV)  are  formed.  Vesicular  suspension  has  been  characterized  by
transmission  electron  microscopy,  dynamic  light  scattering,  confocal  laser  scanning
microscopy, dye entrapment and release studies. 
7. Ijeoma F. Uchegbu et al., summarized the achievements in the niosomes field. A 
number of groups worldwide have studied non-ionic surfactant vesicles (niosomes) with a 
view to evaluating their potential as drug carriers. Niosomes may be formed form a diverse 
array of amphiphiles. The self assembly of surfactants into niosomes is governed by the 
nature of the surfactant, the presence of membrane additives, the nature of the drug 
encapsulated and the actual method of preparation. The influence of formulation factors on 
niosome stability is also examined. Niosomes have been evaluated as immunological 
adjuvants, anti-cancer: anti-infective drug targeting agents, carriers of anti-inflammatory 
drugs, in diagnostic imaging, achieve transdermal and ophthalmic drug delivery.
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8. Sandeep Kumar Sharma et al., prepared the niosomes with different molar ratios of
surfactant and cholesterol using the drug fluconazole. Their morphological properties have
been  determined  by  scanning  electron  microscopy.  Furthermore,  the  release  profile,
entrapment  efficiency,  size  distribution  and  stability  of  these  niosomes  under  various
temperatures were studied.
9. Mahmoud Mokhtar Ahmed Ibrahim et al., formulated and evaluated proniosomal
transdermal  carrier  systems  for  flurbiprofen.  Proniosomes  were  prepared  using  various
non-ionic  surfactants,  namely span  20,  span  40,  span  60  and  span  80  without  and  with
cholesterol  at  percentages  ranging  from  0%  to  50%.  The  effect  of  surfactant  type  and
cholesterol content on drug release was investigated. Drug release was tested by diffusion
through cellophane membrane and rabbit skin; rabbit skin showed lower drug diffusion rates
compared  to  cellophane  membrane.  Drug  release  studies  showed  the  proniosomal
composition controlled drug diffusion rates to be either faster or slower than the prepared
flurbiprofen  suspensions  in  HPMC  gels  or  distilled  water,  respectively.  Microscopic
observations  showed  that  either  proniosomal  solutions  or  gel  formulations  immediately
converted to niosomal dispersions upon hydration. 
10.  Jia-You Fang et al., elucidated the skin permeation and partitioning of a fluorinated
quinolone antibacterial agent, enoxacin, in liposomes and niosomes, after topical application.
In vitro percutaneous absorption experiments were performed on nude mouse skin with Franz
diffusion cells. A significant relationship between skin permeation and the cumulative amount
of enoxacin in the skin was observed. Both permeation enhancer effect and direct vesicle
fusion  with  stratum corneum may contribute  to  the  permeation  of  enoxacin  across  skin.
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Formulation with niosomes demonstrated a higher stability after 48 h incubation compared to
liposomes. The inclusion of cholesterol improved the stability of enoxacin liposomes. 
11. Ismail A. Attia et al., demonstrated the preparation of acyclovir niosomes in a trial to
improve  its  poor  and  variable  oral  bioavailability.  The  niosomes  were  prepared  by  the
conventional  thin film hydration method. The % entrapment was found to be ~11%. The
vesicles have an average size of 0.95 µm and a size range of 0.4 to 2.2 µm. Most of the
niosomes have unilamellar spherical shape. The niosomal formulation exhibited significantly
retarded  release  compared  with free  drug.  The in  vivo  study revealed  that  the  niosomal
dispersion  significantly  improved  the  oral  bioavailability  (more  than  2-fold  increase)  of
acyclovir  in rabbits.  The niosomal dispersion showed significant  increase in the MRT of
acyclovir reflecting sustained release characteristics. 
12. Manivannan Rangasamy et al., explained the acyclovir niosome preparation with
different  ratios  of  (1:1,  1:2,  1:3)  cholesterol  and  Span  80  using  hand  shaking and  ether
injection process. The vesicles were in size range of 0.5-5 µm (hand shaking process) and
0.5-2.5  µm (ether  injection  process).  The  order  of  entrapment  efficiency increases  when
Span  80  concentration  was  increased.  In  vitro  release  study  indicates  76.64%  for
CHOL: Span 80 (1:1) formulation; takes an extended period of 1 day & 16hrs for release. 
13. Pratap S. Jadon et al., developed griseofulvin niosomes to improve its poor and
variable oral bioavailability. Niosomes were prepared by using span 20, span 40, and span 60.
The formulations prepared by thin film method and ether injection method. The influence of
different  formulation  variables  such  as  surfactant  type,  surfactant  concentration,  and
cholesterol concentration was optimized for size distribution and entrapment efficiency for
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both methods. Higher entrapment efficiency obtained with span 60 niosomes prepared by thin
film method. The niosomal formulation exhibited significantly retarded in vitro release as
compared  with  free  drug.  The  in  vivo  study  revealed  that  the  niosomal  dispersion
significantly improved the oral bioavailability, AUC of griseofulvin. 
14. Abdul Hasan Sathali A. et al.,  developed terbinafine Hcl niosomes to the fungal
affected cells for targeted delivery. Niosomes formulated by thin film hydration method using
different  ratios  of  non  ionic  surfactant  (Tween 20,  40,  60,  and  80)  and  cholesterol  with
constant  drug  concentration.  The  formulations  evaluated  for  its  vesicle  size  (by  AFM),
entrapment efficiency (by dialysis method) in vitro release studies and antifungal activities.
The formulation with surfactant cholesterol ratio 2:1 in each group of surfactant showed good
entrapment. Niosomes tested for in vitro antifungal activity using the strain Aspergillus niger
and  compared  with  pure  drug  solution  (as  standard)..  The  best  (Tween  40  niosomes)
formulation incorporated into gel bases and evaluated.
15. Ghada Abdelbary et al., investigated the feasibility of using niosomes as carriers for the
ophthalmic  controlled  delivery of  gentamicin  sulphate.  Niosomes  prepared  using  various
surfactants (Tween 60, Tween 80 or Brij 35), cholesterol and a negative charge inducer DCP
in  different  molar  ratios  by  thin  film  hydration  technique.  The  entrapment  efficiency
determined by centrifugation. Photomicroscopy, TEM and particle size analysis used to study
the  morphology and  size  of  niosomes.  Ocular  irritancy test  performed on  albino  rabbits,
showed no sign of irritation for all tested niosomal formulations.
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16. Kandasamy Ruckmani et al., evaluated the effect of process-related variables like
hydration  time,  sonication  time,  rotation  speed  of  evaporation  flask,  changes  in  osmotic
shock,  viscosity,  the  effects  of  charge-inducing  agent,  centrifugation  on  entrapment  and
release from zidovudine niosomes. Formulation of zidovudine niosomes was optimized by
altering the proportions of Tween, Span and cholesterol. Non-sonicated  niosomes were in the
size range of 2-3.5 µm and sonicated niosomes had a mean diameter of 801 nm. Niosomes
formulated with Tween 80 entrapped high amounts of drug and the addition of DCP enhanced
drug release for a longer time (88.72% over 12 h). The mechanism of release was the Fickian
type and obeyed first-order release kinetics. 
17. Sankar V. et al.,  developed salbutamol sulphate niosomes to reduce the side effects
during asthma treatment. Niosomes prepared by thin film hydration method. Highest % EE
was  found  in  span  60  formulation.  The  tissue  distribution  studies  were  carried  out  to
determine the concentration of drug in lungs when given in niosomal form by using 4 groups
of male mice. Pharmacokinetic studies were carried to predict the existence of drug in the
systemic circulation by using 3 groups of New Zealand rabbits.  It  showed that  enhanced
tissue distribution and extended release of salbutamol sulphate when given in niosomal form.
18. Varaporn Buraphacheep Junyaprasert et al., investigated an influence of different
types  of  membrane additives  including negative charge (dicetylphosphate,  DCP),  positive
charge (stearylamine, STR) and non-ionic molecule (cholesteryl poly-24-oxyethylene ether,
SC24) on the physicochemical properties of drug-free and drug-loaded niosomes. Salicylic
acid selected as a model drug. The niosomes were composed of 1:1 mole ratio of Span 60:
cholesterol as vesicle forming agents. Addition of the membrane additives changed the zeta
potential depending on the type of the additives. Transmission electron microscopy revealed
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that niosomes had unilamellar structure. The particle sizes of all developed niosomes were
between 217 to 360 nm. All niosomes showed no leakage of the salicylic acid after 3 months
of storage indicating the good stability.
19. Tamizharasi S. et al., formulated gliclazide-loaded niosomes and evaluated for their
in vitro as well as  in vivo characteristic in an attempt to improve the oral bioavailability.
Microscopic observation confirmed that all particles were uniform in size and shape. The
entrapment efficiency determined dialysis method. The in vitro release studies exhibited a
prolonged drug release over a period of 24 h. The positive values of zeta potential indicated
that the gliclazide niosomes were stabilized by electrostatic repulsive forces. The niosomes
showing maximum entrapment and suitable release rate were selected for in vivo evaluation. 
20. Vijay Prakash Pandey et al.,  demonstrated the ofloxacin niosomes formation, to
overcome  ofloxacin  eye  drop  solution  drawbacks  (poor  bioavailability)  characterization.
Niosomes prepared by lipid film hydration method using span 60 and cholesterol (various
molar ratios); Characterized for entrapment efficiency, in-vitro drug release, surface charge,
rheological  character,  physical  stability,  minimum  inhibitory  concentration,  in-vivo  drug
release and ocular irritation studies. The span 60: cholesterol in molar ratio of 100:60 showed
higher entrapment of drug and released 73.77 % at 10th hr and the availability of drug in the
aqueous humor was 4.373µg/ml (Cmax), confirmed by HPLC method. The histopathology
study also confirmed the safe use of niosomes. 
21.  Shyamala Bhaskaran et al.,  investigated niosomes containing salbutamol sulphate
using  Span  60  as  the  surfactant,  by  employing  different  techniques  namely,  thin  film
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hydration,  hand  shaking,  ether  injection,  lipid  layer  hydration  and  trans  membrane  pH
gradient method. The drug entrapment efficiency varied from 62 % to 87 %. Transmembrane
pH gradient method was found to be most satisfactory which released 78.4 % of drug in 24 h.
Tissue distribution studies in albino rats and bio- availability studies in rabbits were carried
out.
22. Anitha R. Desai et al., explained about the improvement in the efficacy, reduced
toxicity and enhancement of therapeutic index of niosome carrying α-lipoic acid. Niosomes
were prepared by reverse phase evaporation method using span and tween (20 and/or 60) and
characterized  for  size  reduction,  entrapment  efficiency,  invitro  drug  release  profile  and
stability  under  specific  conditions.  The  diameter  of  niosome  ranges  from  1-3µm  with
spherical/ oval shape. Stability studies proved that optimum storage condition for niosomes
was found to be 4ºC.
23. Raja Naresh R.A. et al., explained about diclofenac Na niosomes comprising Tween
85 & Tween 85-poloxamer F 108 mixture. Anti-inflammatory efficacy of these niosomes was
compared with that of free diclofenac Na in adjuvant induced arthritic rats. It was found that
the niosomal diclofenac Na formulations prepared by employing a 1:1 combination of Tween
85 & poloxamer F 108 elicits a better and consistent anti-inflammatory activity for more than
72 hrs after administration of a single dose.
24. Ajay  B.  Solanki  et  al., optimized  the  composition  of  niosomes  containing
aceclofenac for transdermal application, with a view to improve permeation of drug during an
extended period of  time. Niosomes were prepared by thin film hydration technique. A 32
factorial design was utilized to study the effect of the molar ratio of drug to lipid (X1) and
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volume of hydration medium (X2) on percentage drug entrapment (PDE) and vesicle size.
Selected batches of  niosomes were incorporated in to carbopol  gel  matrix  to prepare the
niosomal gel formulations, which were evaluated for in-vitro release, skin permeation and in
vivo studies. It was evident from the derived polynomial equations and constructed contour
plot, a decrease in the level of X1 and an increase in the X2 lead to an increase in PDE and
decrease in vesicle size. The polynomial equations and contour plot predicted the levels of
independent variables  X1 and  X2 (0.19 and 0.46 respectively), for maximized response of
PDE with constraints on vesicle size. 
25. Anitha R. Desai et al., explained about the improvement in the efficacy, reduced
toxicity and enhancement of therapeutic index of niosome carrying α-tocopherol. Niosomes
were prepared by reverse phase evaporation method using span and tween (20 and/or 60) and
characterized  for  size  reduction,  entrapment  efficiency,  invitro  drug  release  profile  and
stability  under  specific  conditions.  The  diameter  of  niosome  ranges  from  1-5µm  with
spherical/ round shape. Stability studies proved that optimum storage condition for niosomes
was found to be 4ºC.
26. A. Manosroi et al., developed a novel elastic bilayer vesicle entrapped with NSAID, 
diclofenac diethylammonium (DCFD) for topical use. 18 formulations composing of DPPC 
or Tween 61 or Span 60 mixed with cholesterol and ethanol at 0–25% (v/v), by chloroform 
film method with sonication was developed. The elastic Tween 61 niosomes which gave no 
sedimentation, no layer separation, unchanged particle sizes (about 200 nm) were selected to 
entrap DCFD. Transdermal absorption through excised rat skin was performed by vertical 
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Franz diffusion cell at 32±2 ◦C for 6 h. The in vivo anti-inflammatory activity was evaluated 
by ethyl phenylpropiolate (EPP)-induced rat ear edema (n = 3). 
27. Toshimitsu Yoshioka et al., described in which niosomes are dispersed in an aqueous
phase which is then emulsified in an non-aqueous continuous phase. The resultant vesicle
(niosome) –in-water-in-oil (v/w/o) system allows the delivery of vesicles in a non-aqueous
vehicle. The non-ionic surfactants used to prepare the vesicles (niosomes) are also employed
in the emulsification step to minimize surfactant redistribution. The invitro release rate of CF
showed a  decrease in the  order  free solution >vesicle  suspension >w/o emulsion >v/w/o
emulsion.  The  release  rate  of  CF  from  the  v/w/o  system  depends  on  the  nature  of  the
surfactants used. 
28. Prabagar Balakrishnan et  al., reported to  improve the low skin penetration and
bioavailability  characteristics  shown  by  topical  vehicle  for  minoxidil.  Niosomes  were
prepared with thin film hydration method using Brij, Span and cholesterol at various ratios.
The  prepared  systems  were  characterized  for  entrapment  efficiency,  particle  size,  zeta
potential and stability. Skin permeation studies were performed using static vertical diffusion
Franz  cells  & hairless  mouse  skin.  Higher  entrapment  efficiency was  obtained  with  the
niosomes prepared from Span 60, cholesterol at 1:1 molar ratio.
29. Vyas  Jigar  et  al., investigated  that  the  erythromycin  (macrolide  antibiotic)  was
entrapped into niosomes by thin film hydration method to avoid unwanted side effects, to
enhance skin penetration as  well  as  to  improve skin retention.   Various  parameters  were
optimized by partial factorial design. The optimized niosomal formulation was incorporated
into carbopol gel and extensively characterized for PDE & invitro release.
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30.  Anand kumar Y.  et al.,, aimed at developing and optimizing niosomal formulation
of aceclofenac in order to improve its bioavailability. In evaluation study the effect of the
varying  composition  of  non  ionic  surfactant  and  cholesterol  on  the  properties  such  as
encapsulation efficiency, particle size and drug release were studied.  The drug release from
the formulation was evaluated through dialysis membrane and extended over a period of 72 h
in all formulations. The mechanism of dug release was governed by Peppas model.
31. Cosco  D.  et  al.,  evaluated  niosomes  made  up  of  bola,  Span  80  &  cholesterol
(2:5:2  molar  ratio)  are  proposed  as  suitable  delivery  systems  for  the  administration  of
5-fluorouracil  (5-FU),  an  antitumoral  compound  largely  used  in  the  treatment  of  breast
cancer. The bola-niosomes, after sonication procedure, showed mean sizes of ~200 nm and a
loading capacity of ~40% with respect to the amount of 5-FU added during the preparation.
Similar findings were achieved with PEG-coated bola-niosomes. 5-FU-loaded PEG-coated
and  uncoated  bola  niosomes  were  tested  on  MCF-7  and  T47D cells.  Both  bola-niosome
formulations  provided  an  increase  in  the  cytotoxic  effect.  Confocal  laser  scanning
microscopy studies were carried out to evaluate both the extent and the time-dependent bola-
niosome-cell interaction. In vivo experiments on MCF-7 xenograft tumor SCID mice models
showed  a  more  effective  antitumoral  activity  of  the  PEGylated  niosomal  5-FU  at  a
concentration ten times lower        (8 mg/kg) than that of the free solution of the drug (80
mg/kg) after a treatment of 30 days.
32. Naresh Ahuja et al., prepared the niosomes containing lansoprazole (antacid and anti
ulcer agent) by using reverse phase evaporation method. Non-ionic surfactant Span 60 was
use to prepare the formulations. Niosomes are characterized for its entrapment efficiency, size
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range and invitro release of drug. For release study the phosphate buffered saline pH 8.6 was
used and the samples were assayed by UV. 
33. Udupa  N.,  Chandraprakash  K.S.  et  al., examined  the  methotrexate  (MTX)
niosomes by preparing it using the thin film hydration method with Tween 80, 60, 40, Span
60,  40  and  20.  The MTX- entrapped  niosomes were  separated from the  unentrapped  by
dialysis.  Measurement  of  niosome  size  was  made  by  using  a  microscope  with  a  mean
diameter 4.5µm. The entrapment efficiency has also been observed to be greater for Span 60
and least for Tween 80 containing niosomes. The reason may be attributable to the increased
lipophilicity of Span 60. The order of entrapment efficiciency increase as the lippophilcity
increased.
34. Jia  You  Fang  et  al., investigated  the  skin  permeation  of  estradiol  from  various
proniosomes gel formulations across excised rat skin in vitro. The encapsulation efficiency
and  size  of  niosomal  vesicles  formed  from  proniosomes  upon  hydration  were  also
characterized. The % encapsulation of proniosomes with span surfactants showed a very high
value of =100%. Proniosomes with span 40 and span 60 increased the permeation of estardiol
across  skin.  Both  penetration  enhancer  effect  of  non-ionic  surfactant  and  vesicle-skin
interaction  may  contribute  to  the  mechanisms  for  proniosomes  to  enhance  estradiol
permeation.
35.  Pavala Rani  .N. et al., studied that niosomes are vesicles mainly consisting of non-
ionic surfactants that encloses and encompasses the drug molecules. Niosomes of rifampicin
and gatifloxacin were prepared by lipid hydration technique using rotary flash evaporator.
The prepared rifampicin and gatifloxacin niosomes showed a vesicle size in the range of
Page No: 60
Chapter IV                                                                 Literature Review
100-300nm, the entrapment efficiency were 73% and 70% respectively. The  invitro  release
study showed that 98.98% and 97.74% of release of rifampicin and gatifloxacin niosomes
respectively.  The  bactericidal  activities  of  the  niosomal  formulation  were  studied  by
BACTEC radiometric  method  using  the  resistant  strains  (RF 8554)  and  sensitive  strains
(H37Rv)  of  Mycobacterium  tuberculosis  which  showed  greater  inhibition  and  reduced
growth index. 
36. Sambhakar S et al., prepared niosomes containing cefuroxime axetil was prepared
by film formation method by Span 40, 60 and 80 to overcome the bioavailability problem
(25%).  It is characterised by SEM for particle size and morphology. Entrapment efficiency
and release study was carried out by dialysis. In-vitro absorption study was carried out by
everted sac method and also the stability study of niosomes in presence of bile salts was
determined. The vesicle size was found to be less than 5 µm and its polydispersity index was
very low. Entrapment efficiency was found as Span 60 > Span 40 > Span 80. The in-vitro-
release study indicated the controlled release profile of niosomes. 
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CHAPTER-V
SCOPE OF WORK
            Hypertension (or) high blood pressure is a medical condition where in the blood
pressure is chronically elevated. Persistent hypertension is one of the risk factors for strokes,
heart failure and arterial aneurysm, and is a leading cause of chronic renal failure.
Anti hypertensive drugs act by reducing the cardiac output and / or reducing the
total  peripheral  resistance,  without  correcting  the  cause.  Anti  hypertensive  drugs  may
ultimately reduce BP in humans by more than one mechanism. Further, the hemodynamic
alterations produced by a single parenteral dose of a given drug may differ from the effects
resulting from its prolonged oral administration [59].
Ramipril,  a  potent  anti  hypertensive  drug  is  almost  completely converted  to  its
active metabolite ramiprilat (a dicarboxylic acid) by hydrolytic cleavage of the ester group in
the liver, which has about 6 times the angiotension – converting enzyme inhibitor activity of
ramipril.  Ramipril  categorized  as  a  class  IV  /  II  drug  according  to  biopharmaceutical
classification system (BCS) because of its low solubility and poor permeability. Ramipril is a
highly  lipophilic  log  P (octanol  /  water)  3.22,  poorly  water  soluble  drug  with  absolute
bioavailability of 28 – 30% of variable oral absorption. The poor oral bioavailability is due to
the poor / low solubility and poor permeability [52].
Ramipril undergoes significant ‘first pass metabolism’. The half life of ramipril and
its metabolite is 2 and 18 hrs respectively.
Based on these, the purpose of this study is to prepare ramipril niosomes in a trial to improve
its poor oral bioavailability and also to evaluate process related variables like sonication time,
hydration time, osmotic shock, rotational speed of evaporator flask and the effects of charge
inducing agent and release from niosomes. Ramipril niosomes were formulated by thin film
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hydration method using different  ratios  of  non-ionic  surfactant  (Span 60,  40,  20,  80 and
Tween 60) and cholesterol with constant drug concentration.
Because niosomes, an alternative colloidal carrier (transport) system having ability
to improve the solubility / permeability of lipophilic drugs and enhance drug absorption and
bioavailability. Niosomes improve targeting and stability of drug.
Thus the objective of Niosomes as an alternative colloidal carrier system of ramipril
was formulated by proper adjustment of process parameters to enhance ramipril entrapment
and sustainability of release.
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CHAPTER-VI
PLAN OF WORK
PART-I
1. Determination of max of Ramipril in phosphate buffered saline pH7.4.
2. Calibration curve for the drug in phosphate buffered saline pH7.4
PART-II
1. Formulation of ramipril  loaded niosomes using different  molar ratios of  non ionic
surfactant (Span 60) and constant molar ratio of cholesterol (30µmol) by thin film
hydration method.
PART-III
Evaluation of Ramipril loaded niosomes
1. Determination of drug content
2. Determination of entrapment efficiency
3. In –vitro release studies of niosomes in phosphate buffered saline pH 7.4
PART-IV
The best molar ratio of nonionic surfactant, cholesterol was selected and used 
for the preparations of formulations containing different nonionic surfactants (Span 20. 
Span 40, Span 80, Tween 60).
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PART-V
1. Determination of drug content
2. Determination of entrapment efficiency
3. In –vitro release studies of niosomes in phosphate buffered saline pH 7.4
PART-VI
The  best  formulation  was  selected  and  used  for  various  parameters
optimization.
1. Viscosity determination
2. Effect of sonication time
3. Effect of hydration time
4. Effect of osmotic shock
5. Effect of rotational speed of evaporator flask
6. Effect of charge inducing agents (Stearylamine, Dicetyl phosphate).
PART-VII
Invitro  release  studies  of  ramipril  niosomes  containing  STR(5µmol),
DCP(10µmol) and ramipril drug solution phosphate buffered saline pH 7.4.
PART-VIII
1. Measurement of particle size of ramipril loaded niosomes.
2. Morphological studies of niosomes using scanning electron microscopy
3. Zeta potential measurement of the niosomes using Malvern Zeta Sizer
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PART-IX
1. Differential  scanning calorimetry studies of selected formulations to determine the
status of the drug, nonionic surfactant and cholesterol. 
2. Fourier Transform Infra Red Spectroscopy (FT-IR) studies to determine interaction
between the drug, nonionic surfactant and cholesterol.    
PART-X
Stability studies of niosomes at refrigerated and room temperature.
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CHAPTER-VII
MATERIALS AND EQUIPMENTS
MATERIALS USED   
1. Drug- Ramipril                                    - Madras Pharmaceuticals.
2. Cholesterol                                    - S.D.Fine chem. Ltd
3. Sorbiton monolaurate            - Loba chemie
4. Sorbiton monopalmitate                                            - Loba chemie
5. Sorbiton monostearate                                               - Loba chemie
6. Sorbiton monooleate                                                  - Loba chemie 
7. Polyoxyethylene-20 sorbitan monostearate             -S.D.fine Chem Ltd.    
8. Chloroform             - Rankem
9. Methanol - Rankem
10. n-propanol - Nice Chemicals
11. Sodium chloride - Central drug house                   
12. Potassium dihydrogen ortho phosphate - Nice chemicals
13. Disodium hydrogen ortho phosphate - Qualigens
14. Dialysis memebrane 50 – LA 387 - Himedia
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EQUIPMENTS USED
1. Rotary Flash Evaporator - Super fit rotary flash evaporator 
2. Ultra Sonicator - Vibronic’s Ultrasonic processor
3. Electronic Balance - A&D Company, Japan
4. Magnetic Stirrer - MC Dalal & co 
5. UV Visible Spectrophotometer - UV Pharma Spec 1700, Shimadzu
6. Cooling Centrifuge Apparatus           - Eppendorf Centrifuge 5417R
7. Particle size analyzer - Blue wave
8. Malvern zeta sizer - Malvern zeta sizer Nano ES-90
9. Scanning electron microscope - Hitachi S-3400
10. FT-IR Spectrophotometer - Shimadzu
11. Differential Scanning Calorimeter - Perkin Elmer STA 6000 Thermal Analyzer
12. Refrigerator - Kelvinator 
13. Environmental  chamber - Inlab equipments(Madras) Pvt. Ltd
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CHAPTER-VIII
DRUG PROFILE
RAMIPRIL [36, 37, 38, 39, 40, 41, 42, 43, 44, 68, 70, 71].
Synonym:
Ramiprilum
Structure                               
Systematic IUPAC name
                  (2S, 3aS, 6aS) -1- [(2S) -2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-
yl]amino]propanoyl]-3,3a,4,5,6,6a- hexahydro-2H-cyclopenta[d]pyrrole-2-carboxylic acid.
Chemical  Formula                
C23H32N2O5
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Description  
Nature : White crystalline powder
Solubility : Freely soluble in methanol,
Sparingly soluble in water.
Melting point : 109°C 
                      Molecular weight :           416.511gm/mol
Log P (octanol/water) :           3.32(Ramipril)
Octanol/water  partition coefficient    : 0.06 (Ramipril)
0.006 (Ramiprilat)
pKa : 3.1, 5.6 (Ramipril)
1.55, 3.44 (Ramiprilat)
Category
 Angiotensin-converting Enzyme Inhibitors.
 Antihypertensive Agents.
Identification
UV light absorption at 207 nm.
Pharmacodynamic Properties
Ramipril an angiotensin-converting enzyme inhibitor ( ACE inhibitor). Ramipril an
inactive prodrug is converted to active metabolite ramiprilat in liver. Ramiprilat the active
metabolite  competes  with  angiotensin  converting  enzyme  blocking  the  conversion  of
angiotensin I to angiotensin II. It is a vasoconstrictor and a negative feedback mediator for
renin activity. Lower concentrations result in decrease in blood pressure and an increase in
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plasma  renin.  Ramiprilat  may also  act  on  kininase  II,  an  enzyme identical  to  ACE that
degrades vasodilator bradykinin. 
Pharmacokinetic Properties
Absorption
 Extent of absorption in gastrointestinal tract is atleast 50 % to 60 %.
 T max is 1 hour for parent compound, 2 to 4 hour for metabolite.
 Plasma half life 2 to 4 hours.
Metabolism
 Ramipril is converted to active metabolite Ramiprilat in liver by the enzyme 
 Ramiprilat has 6 times greater ACE inhibition activity than the parent 
compound.
Excretion 
 60 % of parent compound and metabolites are excreted in urine.
 40 % of parent compound and metabolites are excreted in faeces.
 Less than 2 % of unchanged drug excreted in urine.
Pharmacokinetic Characters of Ramipril
 Oral Bioavailability : 28 %  ( Ramipril )  
44% (Ramiprilat )
 Excretion : Renal (60 %), 
Fecal (40 %).
 Plasma protein binding : 73 %  ( Ramipril )  
56 % ( Ramiprilat )
Therapeutic Indications
 Control of hypertension;
 Treatment of congestive heart failure;
 Myocardial Infarction;
 To prevent stroke, cardiovascular death;
 Diabetic nephropathy with microalbuminuria.
Dose
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5 to 10 mg per day.
Storage
Protected from light.
Side Effects
 Postural Hypotension
 Hyperkalemia
 Dry cough
 Angio edema
 Neutropenia
 Agranulocytosis
 Anaphylactic reactions
 Nausea
 Vomiting
 Dizziness
 Change in amount of urine
 Yellowing of eyes or skin, dark urine
Drug Interactions
 Hyperkalemia with potassium sparing diuretics and potassium supplements.
 Antacids reduce bioavailability of Ramipril.
 Indomethacin  (and other NSAIDS) attenuate the hyoptensive action.
 Tizanidine increases the risk of hypotension with the ACE inhibitor.
Special Precautions
 Do not take  potassium supplements without seeking medical advice
 Do not take during pregnancy.
Contra-indications
 Reno vascular disease.
 Severe renal impairment.
 History of angio edema.
 During Pregnancy.
 Hypotension. 
 High-dose diuretic therapy.
 Salt and water-depleted states.
 Use of potassium-sparing diuretics.
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International Brand Names
 Acovil (Spain)  
 Cardace (India, Indonesia) 
 Delix (Germany, Turkey) 
 Hyperil (ID) 
 Hypren, (Austria)
 Lostapres (Argentina) 
 Ramace (Australia)
 Tritace (Argentina, Australia ) 
 Unipril (Italy)
 Vesdil, Promed (Germany).
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CHAPTER-IX
EXCIPIENTS PROFILE
SORBITAN MONOLAURATE [45]
SYNONYM
 Arlacel 20; Crill 1; Liposorb L;  Montane 20; Sorbitan laurate; Span 20.
CHEMICAL NAME
 Sorbitan mono dodecanoate.
EMPIRICAL FORMULA
C18 H34 O6
MOLECULAR WEIGHT
346
DESCRIPTION
Yellow viscous liquid. 
METHOD OF MANUFACTURE
Sorbitol  is  dehydrated  to  form  a  hexitan  (1,4-sorbitan),  which  is
then     esterified   with the desired fatty acid.
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PROPERTIES
Acid value          – ≤7
Hydroxyl value             – 159-169
Saponification value     – 159-169
Density       1.01g/cm3
HLB Value   –  8.6
FUNCTIONAL CATEGORY
 Emulsifying agent
 Nonionic surfactant
 Solubilizing agent
 Wetting agent
 Dispersing / suspending agent. 
STABILITY
 Gradual soap formation occurs with strong acids or bases
 Stable in weak acids or bases.
STORAGE
It should be stored in a well-closed container in a cool, dry place.
SAFETY
Daily intake  according to the WHO limit is about 25mg/Kg body weight .
HANDLING PRECAUTIONS
Eye protection and Gloves are recommended.
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SORBITAN MONOPALMITATE [45]
SYNONYM
 Arbunol S-40; Alracel  40;  Crill  2;  Liposorb P;  Montane 40; Sorbitan palmitate;
Span 40.
CHEMICAL NAME
 Sorbitan mono hexadecanoate.
EMPIRICAL FORMULA
C22 H42 O6
MOLECULAR WEIGHT
403
DESCRIPTION
Cream solid. 
METHOD OF MANUFACTURE
Sorbitol  is  dehydrated  to  form  a  hexitan  (1,4-sorbitan),  which  is
then     esterified   with the desired fatty acid.
PROPERTIES
Acid value          – 3-7
Hydroxyl value             – 270-303
Saponification value     – 142-152
Melting point      43-48ºC
Density (g/cm3)    – 1.0g/cm3
HLB Value    –  6.7
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FUNCTIONAL CATEGORY
 Emulsifying agent
 Nonionic surfactant
 Solubilizing agent
 Wetting agent
 Dispersing / suspending agent.
STABILITY
 Gradual soap formation occurs with strong acids or bases
 Stable in weak acids or bases.
STORAGE
It should be stored in a well-closed container in a cool, dry place.
SAFETY
Daily intake according to the WHO limit is about 25mg/Kg body weight.
HANDLING PRECAUTIONS
Eye protection and Gloves are recommended.
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SORBITAN MONOSTEARATE [45]
SYNONYM
 Arbunol S-60; Alracel 60;  Crill  3; Liposorb S-K;  Montane 60; Sorbitan stearate;
Span 60; Tego SMS.
CHEMICAL NAME
 Sorbitan mono-octadecanoate.
EMPIRICAL FORMULA
C24 H46 O6
MOLECULAR WEIGHT
431
DESCRIPTION
Cream solid. 
METHOD OF MANUFACTURE
Sorbitol  is  dehydrated  to  form  a  hexitan  (1,4-sorbitan),  which  is
then     esterified   with the desired fatty acid.
PROPERTIES
Acid value         – 5-10
Hydroxyl value             – 235-260
Saponification value     – 147-157
HLB Value   –  4.7
Melting point      53-57ºC
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FUNCTIONAL CATEGORY
 Emulsifying agent
 Nonionic surfactant
 Solubilizing agent
 Wetting agent
 Dispersing / suspending agent.
STABILITY
 Gradual soap formation occurs with strong acids or bases
 Stable in weak acids or bases.
STORAGE
It should be stored in a well-closed container in a cool, dry place.
SAFETY
Daily intake according to the WHO limit is about 25mg/Kg body weight .
HANDLING PRECAUTIONS
Eye protection and Gloves are recommended.
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SORBITAN MONOOLEATE [45]
SYNONYM
 Albunol  S-80;  Arlacel  80;  Crill  4;  Liposorb  O;   Montane  80;  Sorbitan  oleate;
Span 80;  Tego SMO.
CHEMICAL NAME
 (Z)-Sorbitan mono-9-octadecanoate.
EMPIRICAL FORMULA
C24 H44 O6
MOLECULAR WEIGHT
429
DESCRIPTION
Yellow viscous liquid. 
METHOD OF MANUFACTURE
Sorbitol  is  dehydrated  to  form  a  hexitan  (1,4-sorbitan),  which  is
then     esterified   with the desired fatty acid.
PROPERTIES
Acid value         – ≤8
Hydroxyl value             – 193-209
Saponification value     – 149-160
Density      1.01g/cm3
HLB Value   –  4.3
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FUNCTIONAL CATEGORY
 Emulsifying agent
 Nonionic surfactant
 Solubilizing agent
 Wetting agent
 Dispersing / suspending agent.
STABILITY
 Gradual soap formation occurs with strong acids or bases
 Stable in weak acids or bases.
STORAGE
It should be stored in a well-closed container in a cool, dry place.
SAFETY
Daily intake according to the WHO limit is about 25mg/Kg body weight.
HANDLING PRECAUTIONS
Eye protection and Gloves are recommended.
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POLYSORBATE 60 [45]
SYNONYM
Atlas 70K; Crillet 3; Glycosporse S-20; Liposorb S-20; Polyoxyethylene 20 stearate;  
Sorbitan monooctadecanoate; Tween 60, Tween 60K, Tween 60 VS.
CHEMICAL NAME
 Polyoxyehylene 20 sorbitan monostearate.
EMPIRICAL FORMULA
C64 H126 O26
MOLECULAR WEIGHT
1312
DESCRIPTION
Yellow oily liquid. 
METHOD OF MANUFACTURE
Polysorbates  are  prepared  from  sorbitol  in  a  three-step  process.  Water  is
initially removed  from the  sorbitol  to  form a  sorbitan  (a  cyclic  sorbital  anhydride).  The
sorbitan is then partially esterified with a fattyacid such as stearic acid to yield a hexiton
ester. Finally, ethylene oxide is chemically added in the presence of a catalyst to yield the
polysorbate.
Page No: 84
Chapter IX                                                                    Excipients Profile
PROPERTIES
Acid value          – 2.0
Hydroxyl value              – 81 – 96
Saponification value       – 45 - 55
HLB Value     –  14.9
Solubility     –    Soluble in ethanol and water.   
                                                          Insoluble in mineral oil and vegetable oil.
FUNCTIONAL CATEGORY
 Emulsifying agent
 Nonionic surfactant
 Solubilizing agent
 Wetting agent
 Dispersing / suspending agent.
STABILITY
 Stable to electrolytes and weak acids and bases.
 Gradual saponification occurs with strong acids and bases.
 It is hygroscopic and shoud be examined for water content prior to use and
dried if necessary.
 Also,  in  common  with  other  polyoxyethylene  surfactants,  prolonged
storage can lead to the formation of peroxides.
STORAGE
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It should be stored in a well-closed container protected from light, in a cool, dry place.
SAFETY
Daily  intake  according  to  the  WHO  limit  is  about  25mg/Kg  body  weight  and
moderately toxic by IV route.
REGULATORY STATUS
GRAS listed; Accepted as food additive; Included in the FDA Inactive Ingredients
Guide (IM, IV, oral, rectal, topical and vaginal preparations).
HANDLING PRECAUTIONS
Eye protection and Gloves are recommended.
CHOLESTEROL[45]
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SYNONYM
Cholesterolum; Cholesterin.
CHEMICAL NAME
Cholest -5- en-3β -ol.
EMPIRICAL FORMULA
C27 H46 O
MOLECULAR WEIGHT
386.67
FUNCTIONAL CATEGORY
 Emulsifying agent
 Emollient
DESCRIPTION
 Cholesterol  occurs  as  white  or  faintly  yellow,  almost  odourless,  pearly  leaflets,
needles, powder or granules.
 On prolonged exposure to light and air, it acquires a yellow to tan color.
PROPERTIES
Boiling Point ̶ 360 oC
Density –1.052g/cm3 for anhydrous form 
Melting Point            –147-150oC
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Solubility ̶ Soluble in acetone and vegetable oils.
 Practically insoluble in water 
 Soluble in chloroform: methanol mixture.      
                                              
STABILITY AND STORAGE CONDITIONS
It is stable, and should be stored in a well-closed container and protected from light.
METHOD OF MANUFACTURE
The  commercial  material  is  normally  obtained  from the  spinal  cord  of  cattle  by
extraction with petroleum ethers, but it may also be obtained from wool fat. Purification is
normally  accomplished  by  repeated  bromination.  Cholesterol  may  also  be  produced  by
entirely synthetic means.
Cholesterol produced from animal organs will always contain cholestanol and other
saturated sterols.
SAFETY
It  is  generally regarded as an essentially non-toxic and non-irritant  material at  the
levels employed as an excipient.
HANDLING PRECAUTIONS
Rubber or plastic gloves, eye protection and a respirator are recommended.
REGULATORY STATUS
Induced in the FDA inactive ingredients.
STEARYLAMINE [46, 47 ]
SYNONYM
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 Octadecylamine; Stearamine; n-Stearylamine;; 1- Octadecylamine;                
n- Octadecylamine;  Monooctadecylamine;  Oktadecylamin.
STRUCTURE
                                            
CHEMICAL NAME
1-Aminooctadecane; 1-Octadecanamine 
EMPIRICAL FORMULA
CH3 (CH2)17NH2
MOLECULAR WEIGHT
269.52g/mol
FUNCTIONAL CATEGORY
Cationic surfactants (disinfectants, fungicides, germicide, leveling agents, hair rinse
bases,  wood  preservatives,  textile  softeners,  dyeing  auxiliaries,  ore  flotation.  pigment
grinding aids. anticaking agents) 
• Amphoteric surfactants and Amine oxides (antistatic agent, textile scouring agent, 
ingredient for low irritation shampoo, liquid detergent, foam booster, oil recovery 
agent) 
Page No: 89
Chapter IX                                                                    Excipients Profile
• Corrosion inhibitors and asphalt emulsifier 
• Dispersants, lubricants, water treatment agents. 
DESCRIPTION
White to off-white solid.
PROPERTIES
Physical state : White to off-white solid.
Melting point : 47 - 53 oC 
Boiling point : 232 oC
Solubility in water : practically insoluble
Solvent solubility : soluble in methanol and chloroform mixture
Amine content : 190-213 mg/g
            Iodine value : 3.0 g/100g
STABILITY AND STORAGE CONDITIONS
It is stable under ordinary conditions, and should be stored in a well-closed container
and protected from light.
SAFETY
It  is  generally regarded as an essentially non-toxic and non-irritant  material at  the
levels employed as an excipients.
HANDLING PRECAUTIONS
Keep away from heat. Keep away from sources of ignition. Empty containers pose a 
fire risk.
DICETYL PHOSPHATE [48]
SYNONYMS
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Phosphoric  acid  dihexadecyl  ester;  Dihexadecyl  hydrogen  Phosphate;
Dihexadecyl phosphate.
STRUCTURE
CHEMICAL NAME
1-Hexadecanol,hydrogenphosphate;bis(hexadecyl)phosphate; 
dicetylhydrogenphosphate;   di-n-hexadecylphosphate.
EMPIRICAL FORMULA
C32H67O4P
MOLECULAR WEIGHT
546.85g/mol
DESCRIPTION
anionic
FUNCTIONAL CATEGORY:
♦ Emulsifying agent.
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♦ Non ionic Surfactant.
♦ Solubilizing agent.
♦ Wetting agent.
PROPERTIES:
Melting point: 74-75 °C (lit.)
STORAGE
It should be stored in a well-closed container at -20º C
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CHAPTER- X
EXPERIMENTAL PROTOCOL
PREPARATION OF CALIBRATION MEDIUM [49]
Phosphate buffered saline pH 7.4
Dissolve 2.38 g of disodium hydrogen phosphate, 0.19 g of potassium dihydrogen
phosphate  and  8.0 g  of  sodium chloride  in  sufficient  quantity of  distilled  water  and  the
volume made up to 1000ml. 
STANDARD CURVE FOR RAMIPRIL.
100mg  of  ramipril  is  accurately  weighed  and  dissolved  in  a  small  quantity  of
methanol and made up to 100ml with the buffer phosphate buffered saline pH 7.4. From this
primary solution 10ml is pipetted out and made up to 100ml with phosphate buffered saline
pH 7.4. From this secondary solution aliquots are taken to produce 5, 10, 15 20, 25, 30, 35,
40, 45, 50µg/ml.
The absorbance of  the resulting solution is  measured at  207nm in the UV-Visible
Spectrophotometer (Shimadzu UV-1700 Pharma spec Japan) using phosphate buffered saline
pH  7.4  as  blank.  The  standard  curve  is  plotted  by  taking  concentration  in  X-axis  and
Absorbance in Y-axis
PREPARATION OF RAMIPRIL LOADED NIOSOMES:
Thin Film Hydration Method [50, 51, 52, 66, 67, 69, 72]
Different ratios of surfactant and cholesterol are used to prepare niosomes as shown in
table no: 8 with the concentration of the drug being the same.
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The  niosome  formulations  are  prepared  by  thin  film  hydration  technique.  The
weighed  amount  of  cholesterol,  non-ionic  surfactant  (cholesterol:  non-ionic  surfactant  in
micromoles) dissolved in 5ml of solvent mixture (Chloroform : Methanol 2:1 ratio). It is then
transferred to a 100ml round bottom flask. A thin film is formed under reduced pressure in a
rotary flash evaporator rotated at 100rpm at 55ºC.
The organic solvent is evaporated to form a dry film on the walls of the flask. An
appropriate amount of ramipril is dissolved in  phosphate buffered saline pH 7.4 and this is
added slowly to the round bottom flask having thin film of surfactant and cholesterol and
vortexed continuously  for a period of 30 minutes at 55ºC, until a good dispersion of the
mixture  is  obtained.  The  niosomal  dispersion  is  collected  and  measured.  The  niosomal
suspension is left to mature overnight at 4ºC.
The empty niosomes also prepared by the same method without the drug.
Drug Content Analysis [53, 54]
The amount of drug in the formulation is determined after lysing the niosomes using
50% n- propanol.
Niosomes preparation equivalent to 500µg of ramipril (1ml) is pipetted out in 100ml
standard flask. To this sufficient quantity of  50% n- propanol is added and shaken well for
the  complete  lysis  of  the  vesicles.  The  volume  is  made  up  to  100  ml  with  the  buffer
phosphate buffered saline pH 7.4.
 The  absorbance  is  measured  at  207nm  in  the  UV-Visible  Spectrophotometer
(Shimadzu UV-1700 Pharma spec Japan) using empty niosomes as blank.
 The drug content is calculated from the standard curve, by using the following
formula,
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                                    Sample Absorbance
            Drug content = × 100.
                                               Standard Absorbance
Estimation of Entrapment Efficiency [55, 56]
Ramipril niosome preparations (1 ml) are centrifuged at 14,000 rpm for 90 minutes at
4ºC  using  a  refrigerated  centrifuge  (Eppendorf,  5417R,  Germany)  in  order  to  separate
niosomes  from unentrapped  drug.  The free  drug  concentration  in  supernatant  layer  after
centrifugation are  determined  at  207  nm using UV-Visible Spectrophotometer  (Shimadzu
UV-1700 Pharma spec Japan). The percentage of drug entrapment in niosomes is calculated
using the following formula
                                   (Total drug – Drug in supernatant)
   % drug entrapment =                   × 100.
                                                                 Total drug
Invitro Release Study [50, 51, 52, 53]
Invitro release pattern of niosomes suspension is carried out by dialysis bag (Himedia
dialysis membrane (mw 12,000) method. The niosomal preparation of ramipril is placed in a
dialysis bag with an effective length of 5 cm which acts as a donor compartment. Dialysis bag
is placed in a beaker containing 250 ml of buffer phosphate buffered saline pH 7.4, which
acts as receptor compartment. The temperature of receptor medium maintained at 37±1ºC and
the medium is agitated at 50 rpm speed using magnetic stirrer. Aliquots of 5 ml samples are
collected at predetermined time and replenished immediately with the same volume of fresh
buffer phosphate buffered saline pH 7.4.  The sink condition is maintained throughout the
experiment. The collected samples are analyzed spectrophotometrically at 207 nm using UV-
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Visible  Spectrophotometer  (Shimadzu   UV-1700  Pharma  spec  Japan).  Each  study  is
performed in triplicate.
 The invitro release studies are also carried out for the pure drug by same method.
OPTIMIZATION OF PROCESS-RELATED VARIABLES
Determination of Viscosity [54]
Viscosity  of  the  formulation  is  determined  using an  Ostwald  viscometer  at  room
temperature.
Effect of Sonication Time [54]
The niosomal formulation containing Span 60 1:1 (30µmol) is subjected to ultrasonic
vibration using  Vibronic’s Ultrasonic Processor. To study the effect of sonication time, the
formulation is subjected to sonication for various time intervals (like 1min, 2mins, 3mins,
4mins and 5mins).  Particle size and entrapment efficiency of the formulation are measured.
Particle size analysis [57, 58]
The mean diameter of niosome in the dispersion is determined by Photon Correlation
Spectroscopy (PCS) at a fixed angle of 90° at 25°C. Particle size is determined by using blue
wave (microtac) using disposable sizing cuvette. 
Effect of Hydration Time [54]
The niosomal formulation containing Span 60 1:1 (30µmol) is hydrated with 5.5 ml of
phosphate  buffered saline  pH 7.4,  for  30  minutes,  45minutes,  60minutes,  75minutes  and
90minutes. The entrapment efficiency of the formulations is calculated by ultracentrifugation
method.
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Effect of Osmotic Shock [54, 55]
The effect of osmotic shock on niosomal formulations is investigated by monitoring
the change in vesicle diameter after incubation of niosome suspensions in media of different
tonicity  1.6%  NaCl  (hypertonic),  0.9%  NaCl  (normal)  and  0.5%  NaCl  (hypotonic).
Suspensions  are  incubated  in  these  media  for  3  hours  and  the  change  in  vesicle  size  is
measured by optical microscopy with a calibrated eyepiece micrometer.
Effect of Rotational Speed of Evaporator Flask [54]
The thickness and uniformity of the film depended upon the rotational speed of the
evaporator flask.  The niosomal formulation containing Span 60 1:1 (30µmol) is  prepared
with the speed of 75 rpm, 100 rpm, and 150 rpm of evaporator flask. The appearance of the
formulations is checked by visual observation. The entrapment efficiency of the formulations
is calculated by ultracentrifugation method.
Effect of charge inducing agents [56]
The effect  of  charge inducing agents  on niosomal  formulations  is  investigated by
measuring the zeta potential  measurement  using Malvern Zeta Sizer  (Malvern Zeta Sizer
Nano ES-90, England). The optimized parameters used to prepare the selected formulation
(F1) to study the effect of charge inducing agents.   The niosomal formulations containing
Span 60 1:1 (30µmol) are prepared with positive charge inducing agent (Stearylamine- STR,
F11-5 µmol),  negative  charge  inducing agent  (Dicetyl  Phosphate-  DCP F12-5µmol,  F13-
10µmol and F14-5µmol) respectively. 
The release studies carried out using dialysis bag method and the zeta potential of the
prepared niosome containing DCP (F12) is measured at Malvern Zeta Sizer using disposable
sizing cuvette. 
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Kinetics of drug release: [50, 54]
To understand the pharmacokinetics and mechanism of drug release, the result of in-
vitro drug release study of niosomes were fitted with various pharmacokinetic equations like
zero  order (cumulative  % release  vs  time),  first  order (log  %  drug  remaining  vs  time),
Higuchi's model (cumulative % drug release vs. square root of time), and the Korsmeyer-
Peppas (log cumulative % drug release vs log time) and Hixson- Crowel models (cubic root
of drug remaining vs time). The r 2 and k values were calculated for the linear curve obtained
by regression analysis of the above plots.  
Scanning electron microscopy [59]
Average  particle  size  and  surface  morphology  of  niosomes  are  evaluated  using
scanning electron microscopy. The sample was spread on an aluminium stub and allowed to
dry at room temperature. The dried sample then was sputter coated with gold for 40 seconds
using  Hitachi  Ion-Sputter  E-1010.  The  images  were  captured  with  the 
Hitachi S-3400 Scanning Electron Microscope.
FT-IR Studies [58, 73]
The possibility of drug-excipients (cholesterol, nonionic surfactants) interactions are
further  investigated  by  FT-IR  spectrum  study.  The  FT-IR  spectrum  of  pure  drug  and
combination  of  drug  with  excipient  are  obtained  by  using  Shimadzu  FT-IR
Spectrophotometer. The scanning range is 450-4000 cm-1 and the resolution is 4cm-1. Samples
are prepared in KBr pellets.
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Differential Scanning Calorimetry [60]
Differential  Scanning  Calorimetry  is  performed using  Perkin  Elmer  STA  6000
Thermal Analyzer. The instrument is calibrated with indium standard. Accurately weighed (it
varies from 3mg-25mg) samples are placed in an open type ceramic sample pans. Thermo
grams are obtained by heating the sample at a constant heating rate of 8ºC/minute. A dry
purge of Argon gas (60ml/min) is used for all runs. Samples heated from 37ºC-400ºC.
Stability studies [50, 61]
The best formulation of ramipril loaded niosomes is subjected to stability studies. The
formulation is stored in two different temperatures, 4±20C, 25±20 C/60% RH±5% RH in an
environmental chamber [Inlab equipments (Madras) Pvt. Ltd] for the period of one month.
The drug content, entrapment efficiency of the formulation is estimated every week.
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CHAPTER- XI
RESULTS AND DISCUSSION
STANDARD CURVE OF RAMIPRIL [49] 
The  max of ramipril was determined by scanning the 10µg/ml of the drug solution in
phosphate buffered saline (PBS) pH 7.4. It showed the λ max of 207nm in phosphate buffered
saline pH 7.4. 
Linear correlation coefficient was obtained for calibration of ramipril in phosphate
buffered saline.  Ramipril  obeys the beer’s  law within the concentration range of 5 to 50
µg/ml.  Calibration  plot  of  ramipril  in  phosphate  buffered  saline  pH 7.4  was  shown  in
figure:10, 11 & table no: 6. The λ max of ramipril is showed in UV graph.
PREFORMULATION STUDIES:
Niosomal formulations were prepared by taking equimolar concentration of (1:1 ratio)
non-ionic surfactant (Span 60) and cholesterol. The concentrations of the formulations are
kept at 20, 30, 40, 50, 60 and 70 µmol with a fixed concentration of ramipril. The entrapment
efficiencies of the formulations were determined by ultracentrifugation process and shown in
table no: 7.The ranges of entrapment efficiency of six niosomal formulations were observed
about  25.94% to 35.30%. From these  formulations,  it  was observed  that  the  formulation
containing  30µmol  concentration  of  non-ionic  surfactant  and  cholesterol had  higher
entrapment  efficiency.  Therefore  concentration  of  cholesterol  was  fixed  a  constant  value
(30µmol) for all formulations. 
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Effect of cholesterol concentration on entrapment efficiency: [62, 63]
Cholesterol is one of the common and essential additives in niosome formulations.
The influence of added cholesterol within the lipid composition was observed by determining
the percentage  entrapment efficiency for the formulations containing molar concentrations
from 20 µmol to 70 µmol table no: 7.
The order of entrapment efficiency as follows;
35.3%  (30µmol)  > 34.11%  (40µmol)  > 32.28%  (20µmol)  > 30.62%  (50µmol)  >  
28.33% (60µmol) > 25.94% (70µmol)
 Inclusion of  cholesterol increases the viscosity of the formulation indicating more
rigidity of the bilayer membrane. Cholesterol has the ability to cement the leaking space in
the bilayer membranes. Cholesterol was found to have little effect on the ramipril entrapment.
However,  a  significant  increase  in  entrapment  efficiency of  ramipril was  obtained  when
30 µmol of cholesterol was incorporated into niosomes prepared from Span 60 followed by a
decrease in entrapment efficiency of the drug upon further increase in cholesterol content, it
was due to when the cholesterol content increases beyond a certain level, it starts disrupting
the regular bilayer structure thereby decreases the drug entrapment. 
 It  was  suggested  that,  the  improvements  in  drug  loading  observed  when  the
concentration  of  cholesterol  30µmol.  And  the  major  reduction  percentage  entrapment
efficiency  when cholesterol  content  was further  increased may be due to  two conflicting
factors: 
(1)  With increasing cholesterol, the bilayer hydrophobicity and stability increased and
permeability decreased which leads to efficiently trapping the hydrophobic drug into bilayers
as vesicles formed. 
Page No: 101
Chapter XI                                                             Results and Discussion
(2) In contrast, higher amounts of cholesterol may compete with the drug for packing
space within the bilayer, hence excluding the drug as the amphiphiles assemble into vesicles. 
Another study suggested that decreasing the entrapment efficiency with increasing
cholesterol  ratio  above a certain  limit  may be due to  the fact  that  increasing cholesterol
beyond  a  certain  concentration  can  disrupt  the  regular  linear  structure  of  vesicular
membranes. Moreover Span 60 have higher phase transition temperature being solid at room
temperature. Below transition temperature cholesterol made the membrane less ordered and
increasing cholesterol has been found to increase membrane fluidity to the extent where the
phase transition is abolished. 
PREPARATION OF RAMIPRIL LOADED NIOSOMES:
Ramipril loaded niosomes was prepared by using increasing molar ratios of non ionic
surfactant (Span 60) and constant molar ratio of cholesterol (30µmol) by thin film hydration
method. From those formulations 1:1 ratio (30µmol) selected due to their higher entrapment
efficiency and used for the ramipril loaded niosomes containing Span 20, Span 40, Span 80
and Tween 60. [66, 67]  The formulation details are shown in table no: 8.
ENTRAPMENT EFFICIENCY
                         In all the formulations, the concentration of cholesterol and surfactant on
entrapment efficiency is considerably significant. The range of entrapment efficiency of the
niosomal formulations were observed about 22.05% to 35.05 % and are shown in table no: 9
& figure 12.
                     Higher entrapment efficiency was obtained with Span 60 niosomes (1:1 ratio
30µmol) may be due to surfactant chemical structure (Span series) and having highest phase
transition temperature. [62, 63, 64]   
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Effect of non-ionic surfactants on entrapment efficiency: 
                     The entrapment efficiency was 35.05 % for F1 formulation whereas it was
30.76 %, 29.16 %, 28.06 %, 27.57 % and 25.28 % for formulations F2, F3, F4, F5 and F6
respectively.  This  explains  that  equimolar  mixture  has  higher  entrapment  efficiency
compared  with  increasing  concentration  of  surfactant  while  cholesterol  content  was
maintained at a constant value.
The order of entrapment efficiency as follows;
35.05 % (F1 1:1) > 30.76 % (F2 1:2) > 29.16 % (F3 1:3) > 28.06 % (F4 1:4) >     
27.57 % (F5 1:5) > 25.28 % (F6 1:6).
 
Figure: 9 Schematic showing the possible hydrogen bonding interaction between 
the β-OH group of the cholesterol and the oxygen primarily at the ketone group and also 
weaker interaction at the ester group. [63]
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It  is  possible  that  the  small  hydrophilic  3  β-hydroxyl  (β-OH)  head  group  of  the
cholesterol in the bilayers is able to position itself in the vicinity of the sorbitan monostearate
ester group and the hydrophobic steroid ring orients itself parallel to the acyl chains of the
non-ionic  surfactant.  This  may in  effect  restrict  the  movement  of  the  acyl  chains  of  the
bilayer. 
As shown in figure: 9 the β-OH group of the cholesterol could form a hydrogen bond
with the oxygen at the ester group of the sorbitan monostearate. However, it is also possible
to form hydrogen bonds at the other oxygen functionalities of sorbitan monostearate, which
enhance the stability of the bilayer.  These interactions result in an increase in membrane
cohesion, as shown by increase in the mechanical stiffness of the membranes. There is only
one  possible  hydrogen  bonding  group  on  the  cholesterol  moiety  and   suggest  that  the
equimolar mixture represents the critical composition at which the two compounds can have
extensive interaction at any of the mentioned sites. 
 According to  Finean (1990)  excessive concentration of cholesterol can cause their
cluster formation leading to non-uniform distribution along the bilayers affecting the integrity
of the membrane. Our studies suggest that a similar scenario may also pertain in niosomal
membranes. 
Effect of non-ionic surfactants on entrapment efficiency:
From  the  above  results,  F1  has  higher  entrapment  efficiency  compared  with
increasing concentration of surfactant while cholesterol content was maintained at a constant
value.  It  indicates that increasing surfactant concentration leads to decrease in entrapment
efficiency of the formulation.
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 The entrapment efficiency of various nonionic surfactants increases in the order
of 
35.05 % (F1 1:1) > 33.54 % (F8 1:1) > 29.42 % (F7 1:1) > 26.05 % (F9 1:1) >     
22.05 % (F10 1:1).
These results explained that the Span 60 has higher entrapment efficiency than other
Span types and Tween 60. This could be due to variation in the surfactant chemical structure.
All span types have the same head group and different alkyl chain. Increasing the alkyl chain
length is leading to higher entrapment efficiency. The entrapment efficiency followed the
trend Sp 60 (C18) > Sp 40 (C16)>Sp 20 (C12)>Sp 80 (C18). Sp 60 and Sp 80 have the same
head groups but Sp80 has an unsaturated alkyl chain. De Gier et al. (1968) demonstrated that
the introduction of double bonds into the paraffin chains causes a marked enhancement of the
permeability of liposomes, possibly explaining the lower entrapment efficiency of the Sp 80
formulation. In addition, table no: 3 shows the phase transition temperatures of the Spans.
                                                            Table no: 3
  From  the
table  Sp  80 has  the
lowest transition temperature amongst all tested spans  (Kibbe, 2000). The span having the
highest phase transition temperature provides the highest entrapment for the drug and vice
versa. [4, 5] 
            
             SPAN 60 > SPAN 40 > SPAN 20 > SPAN 80 > TWEEN 60
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S.No Span type Phase Transition temperature(ºC)
1.
2.
3.
4.
Span 60
Span 40
Span 20
Span 80
53
42
16
-12
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                         The order of entrapment efficiency increased as the liphophilicity increased 
(HLB value decreased). Span 80 has the lowest HLB value but it has an unsaturated alkyl 
chain in its structure leads to lower entrapment efficiency.
   Table no: 4
S.No. Name HLB value
1.
2.
3.
4.
5.
Span 20
Span 40
Span 60
Span 80
Tween 60
8.6
6.7
4.7
4.3
14.9
IN VITRO RELEASE STUDIES
The in vitro drug release study of ramipril loaded niosomes was done using dialysis
bag diffusion technique in phosphate buffer saline pH 7.4. Figure: 13, 14 and table no 10, 11.
In vitro release from niosomes
The cumulative % drug release at 12 hours was 54.5 % for formulation F1
whereas it was 63.8 %, 66.7 %, 70.8 %, 79.9 %, 65.4 %, 77.4 %, 61.4 %, 62.2 % and 94.4 %
for formulations F2, F3, F4, F5, F6, F7, F8, F9 and F10, respectively. Significant changes in
release were observed upon changing the type of surfactant used in the bilayer of ramipril
niosomes. In niosomal formulations the experimental studies showed that the rate of drug
release  depends  on  the  percentage  of  drug  entrapment  efficiency.  This  result  was  in
conformity with the report of “Samar Mansour”[65]
Generally, all niosome formulations showed significant slower release than ramipril
solution  (0.5mg/ml).  This  confirms  that  a  sink  condition  for  ramipril  release  was
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accomplished and the dialysis bag used in the dissolution procedure does not limit ramipril
release.   Niosomal  ramipril  formulations with Span 60,  Span 40,  Span  20,  Span  80 and
Tween 60 show significant reduction in invitro drug release in 12hours compared with pure
drug in solution.
Effect of surfactants on the release rate of ramipril from niosomes:
From the release studies of F1-F6, F1 showed the slower and prolonged drug release
than the other formulations. This is due to higher entrapment efficiency. Further the release
studies of the formulations containing Span 20, 40, 80 and Tween 60 are compared. It showed
the release rate as the following order, 
Tween 60 > Span 20 > Span 80 > Span 40 > Span 60
F10 (94.4%) > F7 (77.4%) > F9 (62.2%) > F8 (61.4%) > F1 (54.5%)
There is no significant difference between the release rates of Span 80 and Span 40
formulations.  The entire amount of loaded drug was not released from the niosomes. This
may be due to entrapment of the drug in the lipophilic region.
Comparison of In vitro drug release of ramipril loaded niosomes with ramipril pure
drug solution:
The release of ramipril from niosomes is much slower and controlled than the ramipril
pure drug solution (0.5mg/ml). Ramipril showed a release of about 96.4 % within 3.5 hours.
The sustained release profile of niosomes was compared with pure drug solution and shown
in table no: 12 and figure: 13, 14.
OPTIMIZATION OF PROCESS RELATED VARIABLES:
Determination of Viscosity [54]
Page No: 107
Chapter XI                                                             Results and Discussion
The viscosity of the selected formulation Span 60 1:1 (30µmol) was determined using
Ostwald’s viscometer. The viscosity of the formulation was found to be 1.15 centipoises.
Effect of Sonication Time [54]
The niosomal formulation containing Span 60 1:1 (30µmol) is subjected to study the
effect  of  sonication time, for various  time intervals (like 1min, 2mins,  3mins,  4mins and
5mins).  Particle size and entrapment efficiency of the formulation are showed at table no: 13
and figure 15 a-f.
The mean particle size and its distribution were measured by dynamic light scattering
technique. From the figures it  showed that  the sonication time 3 minutes yield a smaller
particle size compared with the other sonicated samples. Similar results also obtained with
the  entrapment  efficiency.  Therefore  the  optimal  sonication  time  to  formulate  niosomal
vesicles was found to be 3minutes.
Effect of Hydration Time [54]
The niosomal formulation containing Span 60 1:1 (30µmol) is hydrated with 5.5 ml of
PBS  pH-7.4,  for  30  minutes,  45minutes,  60minutes,  75minutes  and  90minutes.  The
entrapment efficiency of the formulations is  showed at  the table no: 14. From the results
hydration time of 45 minutes leads to higher entrapment efficiency. Therefore the optimal
hydration time to formulate niosomal vesicles was found to be 45 minutes.
Effect of Osmotic Shock [54, 55]
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Formulation was treated with hypotonic (0.5% NaCl),  hypertonic (0.9% NaCl),  or
normal saline (0.9% NaCl) solutions. The effect of osmotic shock is shown in figure no: 16
Increase in vesicle size was observed in formulation significantly in formulation incubated
with  hypotonic  solution.  In  hypertonic  solution,  the  formulation  shrank  uniformly.
Formulations  incubated  with  saline  showed  a  slight  increase  in  vesicle  size.  This
demonstrates that ramipril niosomes could be diluted with normal saline for parenteral use.  
 
Effect of Rotational Speed of Evaporator Flask [54]
The thickness and uniformity of the film depended upon the rotational speed of the
flask. A speed of 100 rpm yielded a uniformly thin lipid film resulting in spherical vesicles on
hydration.  Lower  and  higher  rpm  (75  and  150  rpm)  produced  thick  films  that  formed
aggregates of vesicles on hydration.
Effect of charge inducing agents [56]
Niosomes  were  formulated  with  various  amounts  of  the  charge  inducing  agents,
Stearylamine - STR (5 µmol), and Dicetylphosphate - DCP (5 µmol, 10 µmol and 15 µmol).
The inclusion of  a  charge inducing agent  in  the lipid layer  prevents  the aggregation and
fusion of vesicles, and maintains their integrity and uniformity. The optimal concentration of
DCP in niosomes was identified based on entrapment efficiency. It was found that 10µmol
DCP produced spherical vesicles with increased drug entrapment and without aggregation as
shown in table no: 15.
Role of Charge-inducing Agents in Drug Entrapment:
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The effect of charge on niosome bilayers is a matter of debate. Some reports have
concluded that  negatively charged  liposomes are  more  effective  in  drug entrapment  than
neutral liposomes. The effect of STR and different micromolar concentrations of DCP on
percentage entrapment of Span 60 formulation is shown in Figure:  12. Formulations with
5µmol STR show good entrapment at a surfactant/cholesterol ratio of 1: 1. Formulations of
Span  with  DCP  decreased  drug  entrapment.  In  Span  60  formulation,  DCP  decreased
entrapment whereas in formulation containing STR, entrapment was increased table no: 16.
These results show that inclusion of DCP alters the entrapment; it depends upon the alkyl
side-chain of the surfactant. 
The  inclusion  of  DCP into  ramipril  niosomes  was  found  to  decrease  percentage
entrapment efficiency with respect to the control formulation (F1- without charge inducing
agent) which was presumably due to the electrostatic repulsion forces between the carboxyl
group of ramipril and an anionic head group of DCP. In contrast, the inclusion of STR into
ramipril  niosomes  at  appeared  to  increase  percentage  entrapment  efficiency  of  ramipril
greater  than  the  control  formulation  (F1-  without  charge  inducing  agent),  owing  to  the
electrostatic attraction between the positively charged head group of STR and the carboxyl
group of ramipril [56]. 
Role of Charge-inducing Agents in Drug Release Rate:
The in  vitro  drug release study of  F1,  F11  and F12 was done using dialysis  bag
diffusion technique in phosphate buffer saline pH 7.4. The drug release rate at 12hours for F1
was 54.5%, F11 was 58.5% and F12 was 67.4% [table no: 17]. Inclusion of DCP in Span 60
formulation increased the percent release of drug and extended the time of release compared
with formulation without DCP (Figure: 17, 18, 19).  Similar results were reported for Span 40
and Span 60 by Manconi et al.
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Zeta potential measurement:
The zeta potential of the formulation (F12) containing 10 µmol DCP was measured
using Malvern Zeta Sizer using disposable sizing cuvette. The particle size and the charge on
the vesicle membrane are shown in figure 20a, 20b & 21. The average particle size was found
to be 256.9nm. The Poly Dispersibility Index (PDI) was found to be 0.494. The zeta potential
of the F12 formulation was found to be -84.3mV. 
KINETICS OF DRUG RELEASE [50, 54]
                          Linear regression analysis for the release was done to determine the proper
order of release. From the results shown in table no: 18. Tween 60 formulation follows zero-
order kinetics and the other formulations obey first-order kinetics. Calculation of Higuchi’s
correlation coefficient confirms that drug release was proportional to the square root of time
indicating that ramipril release from niosomes was diffusion controlled. The n value from the
Korsmeyer-Peppas model  for  ramipril niosomal  formulation was between 0.728 and 0.99
which confirms the Non-Fickian type diffusion, follow an anomalous diffusion mechanism
with  erosion  (n>0.54).  Release  profiles  also  fitted  into  a  Hixson-Crowell  model  and
confirmed that drug release from niosomes followed anomalous diffusion. The similar results
were obtained by Ahmed A Guinea et al and Alok Namdeo et al. The drug release pattern
from ramipril loaded niosomes follows Higuchi’s model and first order of release.
  
SCANNING ELECTRON MICROSCOPY (SEM)
Page No: 111
Chapter XI                                                             Results and Discussion
The particle  size,  shape and surface morphology was evaluated using SEM. SEM
photographs of  ramipril  loaded niosome of  selected formulations  F1was observed.  In  the
selected formulation the particles were almost spherical and homogenous. The micrographs
also confirmed that niosomes was in nanometer size. The results showed that the ramipril
loaded niosomes particles have a spherical shape with smooth surface. This is shown in the
figure: 22.
FT - IR STUDIES
FT-IR  studies  were  carried  out  to  confirm the  compatibility  between  drug
ramipril,  the  non-ionic  surfactants  used  (Span  20,  Span  40,  Span  60,  and  Span  80),
cholesterol and niosome formulation. The spectra obtained from the FT-IR studies are from
4400 cm-1 to 450 cm-1.
The FT-IR spectra of the formulations are shown in Figure: 23, 24 a,b, 25 a,b,
26 a,b, & 27 a,b. It  was confirmed that there are no major shifting as well as any loss of
functional  peaks between the spectra of drug, non- ionic surfactant,  cholesterol  and drug
loaded niosome. [73]
The FT-IR spectra of ramipril drug shows as follows:
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Table No: 5
S.No Wave Number (cm-1). Bond
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
3280
3200-3400
2850-2960
1680-1760
1600-1700
1500-1700
1500-1600
1180-1360
1200-1500
700-900
-CH stretching, -NH stretching, -OH stretching
-OH bond (H bonded alcohols and phenols)
Alkanes
Aldehydes, Ketones, Carboxylic acids
-C-C stretching, C=N stretching
-NH bending
C=C (Aromatic rings)
-C-N amines
-OH bending
-NH rocking
DIFFERENTIAL SCANNING CALORIMETRY (DSC Studies) [60]
DSC studies  are  useful  method  of  detecting  drug-excipient  incompatability.  DSC
thermograms of  the pure drug (Ramipril),  Non-ionic surfactants  (Span  40 and  Span 60),
cholesterol and formulations are shown in the figure: 28. 
Drug showed the sharp melting endothermic peak at 109º C. Span 40 showed at 48º C
and Span 60 showed at 57º C. It suggests that the formulation components Span 60, Span 40,
cholesterol and the drug ramipril do not interact to form any additional chemical entity but
remain as mixture.
STABILITY OF RAMIPRIL LOADED NIOSOMES: 
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The stability studies of the selected formulation of ramipril loaded niosomes
was carried out by storing at 40C (refrigeration temperature) and 250C + 20C [2, 15].
The  entrapment  efficiency  of  the  drug  in  the  niosomal  dispersion  was  estimated
immediately  after  the  preparation  and  the  results  are  shown  in  the  table  no:  19.  The
entrapment efficiency of the niosomal dispersion, after every week was estimated and the
results are shown in the table no: 19 and figure 29.
From the table no: 19 and figure: 29, entrapment efficiency of the formulation
stored  at  refrigerated  temperature  (4±20C/60%  RH)  showed  only  a  slight  decrease  after
1month compared to the formulation stored at  (250C  + 20C/60% RH). Hence increase in
temperature and storage period decreases the entrapment efficiency of niosomal dispersion
irrespective of the non-ionic surfactants used for formulations. Comparatively slightly high
entrapment efficiency of drug was observed with niosomes stored in refrigerated temperature.
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CHAPTER XII
SUMMARY AND CONCLUSION
 The purpose of this research was to prepare ramipril loaded niosomes for controlled
release of drug and a trial to improve the bioavailability.
 Thin film hydration technique was employed to produce niosomes using non ionic
surfactants and cholesterol.
 Preformulation studies were conducted to fix the cholesterol concentration used in our
formulations.  From  the  results  it  was  concluded  that  30µmol  concentration  of
cholesterol was fixed and used in all formulations.
 Cholesterol was used as a membrane additive, acts as a stabilizer as well as fluidity
buffer to improve the stability of the vesicles.
  The formulations were prepared by varying the surfactant concentration (Span 60)
and cholesterol concentration fixed at constant value.
 The formulated niosomes were characterized for entrapment efficiency and in vitro
release studies in phosphate buffered saline pH 7.4.
 The niosomal  drug delivery system of  ramipril  prepared from Span 60 equimolar
mixture (1:1) showed better entrapment efficiency and sustained drug release. 
 This  ratio  (1:1)  was  used  to  prepare  the  formulations  by  using  other  non-ionic
surfactants (Span 40, Span 20, Span 80 and Tween 60).
 The  better  entrapment  efficiency  of  niosomes  was  obtained  with  Span  60  about
35.05 % due to the higher lipophilicity (HLB value- 4.7) of the surfactant and the
highest phase transition temperature.
 The order of entrapment efficiency as follows;
 SPAN 60 > SPAN 40 > SPAN 20 > SPAN 80 > TWEEN 60
 The order of invitro release study as follows;
Tween 60 > Span 20 > Span 80 > Span 40 > Span 60
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The sustained drug release from the Span 60 is due to entrapment of the drug in the 
lipophilic region.
 The release of ramipril from niosomes is much slower and controlled than the ramipril
pure drug solution (0.5mg/ml).
 The process  related  parameters  were  optimized  such as  sonication time (3  mins),
hydration  time (45 mins),  osmotic  shock,  rotational  speed of  the evaporator  flask
(100 rpm), and the effect of charge inducing agents such as STR and DCP.
 The  inclusion  of  STR  into  ramipril  niosomes  at  appeared  to  increase  %E.E.  of
ramipril due to the electrostatic attraction between the positively charged head group
of STR and the carboxyl group of ramipril.
 The inclusion of DCP into ramipril niosomes was found to decrease %E.E. due to the
electrostatic repulsion forces between the carboxyl group of ramipril and an anionic
head group of DCP. 
 The zeta potential  of the formulation containing DCP 10µmol (F12) was found to
be - 84.3mV. 
 The drug release pattern from ramipril loaded niosomes follows Higuchi’s model and
first order of release. 
 The particle size of the formulated ramipril niosomes exhibited nanometer size range
spherical  shape  particles.  SEM  analysis  of  the  niosomes  dispersion  showed  the
spherical shape of the vesicles.
 The results of the FT-IR studies and DSC studies proved that no interactions between
the drug, cholesterol, non-ionic surfactants and formulations.
 Stability studies  indicated that  the entrapment  efficiency of  the niosomes was not
affected significantly in the refrigerated storage temperature. However there may be a
slight  reduction  in  the  entrapment  efficiency  of  the  niosomes  due  to  the  drug
expulsion from the vesicles.
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Chapter XII                                                       Summary and Conclusion
 It  is  concluded  that  the  thin  film  hydration  technique,  is  a  useful
method for the successful incorporation of poorly water soluble drug ramipril into
niosomes with high entrapment efficiency. The prolonged release of the drug from the
niosomes suggests that the frequency of administration may be reduced. Further it
may  be  presumed  that  if  the  nanometer  range  particles  are  obtained,  the
bioavailability may be increased. Further investigations in animals, human volunteers,
pharmacological  and toxicological  investigations in animals and human volunteers
may help to exploit the niosomes as prosperous drug carriers for targeting drugs more
efficiently.  Hence we can conclude that niosomes provide controlled release of drug
and these systems are used as drug carriers to enhance the bioavailability of poorly
water soluble drugs.
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Table No-6
CALIBRATION CURVE OF RAMIPRIL IN
PHOSPHATE BUFFERED SALINE pH 7.4. 
S.No. CONCENTRATION(µg/ml) ABSORBANCE ± SD*
1 5 0.196 ± 0.0005 
2 10 0.390 ± 0.007
3 15 0.587 ± 0.0057
4 20 0.781 ± 0.0065
5 25 0.974 ± 0.0045
6 30 1.182 ± 0.0091
7 35 1.382 ± 0.0043
8 40 1.564 ± 0.015
9 45 1.747 ± 0.016
10 50 1.972 ± 0.0087 
          n = 3*                                                                                       γ =  0.999901195        
Table No: 7
ENTRAPMENT EFFICIENCIES OF RAMIPRIL NIOSOMES USING
SPAN 60: CHOLESTEROL (1:1) AT DIFFERENT MOLAR
CONCENTRTIONS.
S.NO MOLAR CONCENTRATION % ENTARPMRNT
EFFICIENCY ± SD*
1 20 µmol 32.28 ± 0.33
2. 30 µmol 35.30 ± 0.17
3. 40 µmol 34.11 ± 0.58
4. 50 µmol 30.62 ±0.69
5. 60 µmol 28.33 ± 0.47
6. 70 µmol 25.94 ± 0.28
n=3*
Table No: 8
FORMULATION OF RAMIPRIL NIOSOMES
S.NO FORMULATION SURFACTANT
RATIO OF
SURFACTANT CHOLESTEROL
1. F1 SPAN 60 1 1
2. F2 SPAN 60 2 1
3. F3 SPAN 60 3 1
4. F4 SPAN 60 4 1
5. F5 SPAN 60 5 1
6. F6 SPAN 60 6 1
7. F7 SPAN 20 1 1
8. F8 SPAN 40 1 1
9. F9 SPAN 80 1 1
10. F10 TWEEN 60 1 1
Drug concentration used in each formulation kept as constant 2.5mg/5ml.
In ratio 1 stands for 30µmol.  
Table No: 9
% ENTRAPMENT EFFICIENCY OF DIFFERENT FORMULATIONS
S.NO FORMULATION SURFACTANT
RATIO OF
% ENTRAPMENT
EFFICIENCY ± SD*SURFACTANT CHOLESTEROL
1. F1 SPAN 60 1 1 35.05±0.46
2. F2 SPAN 60 2 1 30.76±0.65
3. F3 SPAN 60 3 1 29.16±0.56
4. F4 SPAN 60 4 1 28.06±0.71
5. F5 SPAN 60 5 1 27.57±0.39
6. F6 SPAN 60 6 1 25.28±0.50
7. F7 SPAN 20 1 1 29.42±0.57
8. F8 SPAN 40 1 1 33.54±0.65
9. F9 SPAN 80 1 1 26.05±0.70
10. F10 TWEEN 60 1 1 22.05±0.58
n=3*
Table No: 10
COMPARISON OF INVITRO RELEASE PROFILE OF RAMIPRIL NIOSOMES
TIME IN HOURS
CUMULATIVE % DRUG RELEASE  ±  SD*
F1 (SPAN 60 1:1) F2 (SPAN 60 1:2) F3 (SPAN 60 1:3) F4 (SPAN 60 1:4) F5 (SPAN 60 1:5)
0.00 0 ±0 0 ±0 0 ±0 0 ±0 0 ±0
0.25 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
0.5 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
0.75 0 ± 0 3.7 ± 1.80 4.7 ± 0.81 4.8 ± 0.51 5.5 ± 0 .61
1.0 4.1 ± 0.24 7.4 ± 1.09 8.2 ± 1.02 7.7 ± 0.99 8.6 ± 1.32
1.5 7.7 ± 1.71 11.5 ± 0.87 12.3 ± 0.98 13.2 ± 0.69 13.3 ± 1.00
2.0 11.3 ± 1.75 15.7 ± 0.96 16.1 ± 1.84 17.6 ± 1.59 18.4 ± 1.00
2.5 15.9 ± 1.67 19.6 ± 1.46 21.4 ± 1.51 22.6 ± 2.09 25.5 ± 1.49
3.0 19.7 ± 2.54 23.8 ± 1.07 24.3 ± 2.03 26.8 ± 1.88 30.9 ± 1.48
3.5 24.5 ± 2.01 26.5 ± 2.48 29.8 ± 1.42 30.0 ± 2.00 34.9 ± 1.79
4.0 26.7 ± 1.76 29.7 ± 0.75 32.1 ± 1.52 31.7 ± 1.45 39.3 ± 2.20
4.5 29.3 ± 1.10 31.7 ± 1.59 35.5 ± 1.70 34.1 ± 0.70 42.6 ± 1.29
5.0 31.4 ± 1.95 37.0 ±1.62 38.3 ± 1.65 36.1 ± 1.29 44.1 ± 0.89
5.5 33.9 ± 0.60 39.7 ± 0.40 41.1 ± 0.96 40.7 ± 1.29 47.8 ± 1.29
6.0 34.8 ± 0.40 42.6 ± 1.49 42.6 ± 0.47 45.6 ± 1.30 51.0 ±2.09
6.5 37.2 ± 1.04 46.6 ± 1.85 46.0 ± 1.18 49.6 ± 1.30 56.5 ± 0.52
7.0 39.2 ± 0.94 48.6 ± 1.34 50.2 ± 1.07 52.3 ± 0.65 56.9 ± 0.22
7.5 42.6 ± 0.58 50.8 ± 1.17 53.7 ± 0.94 57.0 ± 1.97 60.8 ± 1.89
8.0 44.0 ± 1.16 53.1 ± 1.17 56.0 ± 1.95 61.4 ± 0.83 64.1 ± 0.52
9.0 46.5 ± 1.28 54.7 ±  1.60 58.4 ± 0.96 65.8 ± 0.95 68.1 ± 1.29
10.0 49.7 ± 1.19 59.1 ± 1.10 61.1 ± 1.15 67.0 ± 0.19 71.4 ± 2.39
11.0 52.1 ± 0.02 60.7 ± 1.00 63.2 ± 1.98 69.6 ± 1.05 74.9 ± 1.39
12.0 54.5 ± 0.65 63.8 ± 1.50 66.7 ± 1.57 70.8 ± 1.39 79.9 ± 0.70
n=3*
Table No: 11
COMPARISON OF INVITRO RELEASE OF RAMIPRIL NIOSOMES
TIME IN HOURS
CUMULATIVE % DRUG RELLEASE ± SD*
F6(SPAN 60 1:6) F7(SPAN 20 1:1) F8(SPAN 40 1:1) F9(SPAN80 1:1) F10(TWEEN60 1:1)
0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
0.25 0 ± 0 5.0 ± 0.42 4 ± 0.51 4.1 ± 0.80 4.6 ±0.22
0.5 0 ±0 7.0 ± 0.69 5.9 ± 1.51 6.2 ± 1.18 6.8 ±1.49
0.75 5.2 ±0 .99 10.6 ± 1.39 8.5 ± 1.16 8.2 ± 2.30 9.3 ±1.03
1.0 8.3 ± 1.29 15.3 ± 1.14 11.6 ± 1.14 10.9 ± 1.65 14.0 ±1.09
1.5 11.4 ± 0.59 19.5 ± 1.69 14.0 ± 1.72 15.0 ± 1.25 18.8 ±2.50
2.0 14.6 ± 1.59 23.8 ± 0.59 17.0 ± 1.17 18.1 ± 1.53 23.3 ±1.34
2.5 18.5 ± 1.69 28.4 ± 0.99 19.7 ± 1.16 21.0 ± 1.26 28.2 ±1.28
3.0 22.3 ± 1.99 33.2 ± 0.71 23.7 ± 1.19 23.6 ± 1.98 32.0 ±1.29
3.5 25.6 ± 2.39 36.5 ± 1.30 26.7 ±  1.00 26.0 ± 1.26 36.2 ±1.19
4.0 28.9 ± 1.42 39.1 ± 1.32 30.0 ± 1.20 29.2 ± 1.04 40.8 ±1.34
4.5 32.2 ± 2.21 42.2 ± 0.61 32.4 ± 1.23 32.1 ± 1.03 45.5 ±1.92
5.0 35.9 ± 3.89 44.5 ± 0.91 34.3 ± 1.19 35.6 ± 2.01 49.9 ±1.27
5.5 39.4 ± 2.89 48.7 ± 1.80 38.0 ± 1.15 38.7 ± 1.76 54.5 ±1.08
6.0 42.1 ± 1.51 51.1 ± 1.48 40.5 ± 1.13 40.9 ± 1.26 57.7 ±1.25
6.5 46.2 ± 1.21 53.9 ± 1.23 43.9 ± 1.86 43.8 ± 1.25 61.2 ±1.20
7.0 48.9 ± 1.41 57.4 ± 2.01 46.8 ± 1.26 46.7 ±1.20 65.6 ±0.74
7.5 51.8 ± 0.71 59.9 ± 1.74 49.5 ± 0.01 48.8 ±1.92 70.3 ±1.79
8.0 53.7 ± 0.80 62.8 ± 0.94 51.5 ± 1.24 50.9 ±1.95 74.6 ±1.02
9.0 56.4 ± 1.10 67.4 ± 1.17 52.7 ± 0.25 52.6 ±1.17 79.5 ±1.09
10.0 58.9 ± 1.31 70.4 ± 2.11 55.5 ± 0.92 55.8 ±1.10 84.0 ±1.03
11.0 62.7 ± 1.69 73.9 ± 1.16 58.8 ± 1.62 58.2 ±1.49 88.2 ±1.04
12.0 65.4 ± 0.59 77.4 ± 1.18 61.4 ± 0.74 62.2 ±1.08 94.4 ±1.04
n=3*
Table No: 12
COMPARISON ON INVITRO RELEASE OF RAMIPRIL NIOSOMES (SPAN 60 1:1)
WITH RAMIPRIL DRUG SOLUTION
TIME IN HOURS
CUMULATIVE % DRUG RELEASE±SD*
F1 (SPAN 60 1:1)     PURE DRUG SOLUTION
0 0 ± 0 0 ± 0
0.25 0 ± 0 30.3 ± 0.83
0.5 0 ± 0 43.3 ± 1.40
0.75 0 ± 0 48.6 ± 1.31
1.0 4.1 ± 0.24 54.9 ± 0.70
1.5 7.7 ± 1.71 62.3 ± 1.69
2.0 11.3 ± 1.75 68.1 ± 1.59
2.5 15.9 ± 1.67 75.7 ± 1.49
3.0 19.7 ± 2.54 85.8 ± 2.96
3.5 24.5 ± 2.01 96.4 ± 2.78
4.0 26.7 ± 1.76 97.3 ± 2.67
4.5 29.3 ± 1.10 98.0 ± 1.08
5.0 31.4 ± 1.95 98.7 ± 1.05
5.5 33.9 ± 0.60 98.6 ± 1.13
6.0 34.8 ± 0.40 97.6 ± 0.79
6.5 37.2 ± 1.04 97.3 ± 0.45
7.0 39.2 ± 0.94 97.3 ± 0.67
7.5 42.6 ± 0.58 97.2 ± 1.56
8.0 44.0 ± 1.16 97.1 ± 0.57
9.0 46.5 ± 1.28 96.6 ± 0.94
10.0 49.7 ± 1.19 96.3 ± 1.47
11.0 52.1 ± 0.02 96.0 ± 1.18
12.0 54.5 ± 0.65 95.7  ± 0.60
           n=3*
Table no: 13
EFFECT OF SONICATION TIME (SPAN 60 1:1)
   
Table no:
14
EFFECT
OF
S.NO SONICATION TIME
(MINUTES)
% ENTRAPMENT
EFFICIENCY
1 0 35.90
2 1 38.64
3 2 38.92
4 3 47.22
5 4 42.51
6 5 36.54
S.NO HYDRATION TIME(MINUTES) % ENTRAPMENT EFFICIENCY
1 30 35.22
2 45 52.21
3 60 41.63
4 75 31.04
5 90 13.12
Table No: 16
ENTRAPMENT EFFICIENCIES OF RAMIPRIL NIOSOMES
WITH AND WITHOUT CHARGE INDUCING AGENTS.
S.NO FORMULATION % ENTRAPMENT EFFICIENCY ± SD*
1. F1 35.05±0.46
2. F11 40.53±0.33
3. F12 27.88±0.48
4. F13 20.45±0.88
5. F14 20.62±0.56
      n=3*
Table No: 15
FORMULATION OF RAMIPRIL NIOSOMES WITH AND
WITHOUT CHARGE INDUCING AGENTS. 
S.NO. FORMULATION
 
SURFACTANT :
CHOLESTEROL
(1:1 MOLAR RATIO)
CHARGE INDUCING
AGENTS
STR DCP
1. F1 30 µmol -- --
2. F11 30 µmol 5 µmol --
3. F12 30 µmol -- 10 µmol
4. F13 30 µmol -- 5 µmol
5. F14 30 µmol -- 15 µmol
Drug concentration used in each formulation kept as constant 2.5mg/5ml. 
Table No: 18
DETERMINATTION OF ORDER OF RELEASE OF RAMIPRIL FROM NIOSOMAL FORMULATIONS
     
Formulation
Higuchi
r2
Korsemeyer-
Peppas Zero order First order Hixson-Crowell Release
mechanism
r2 n r2 K0 (%
mg/h)
r2 K1 (h-1) r2 Slope (n)
F1 0.9945 0.9581 0.9853 0.957 4.997 0.9885 0.0306 0.980 0.0968 NFD
F2 0.9926 0.9697 0.9533 0.960 5.800 0.9926 0.0392 0.986 0.1262 NFD
F3 0.9945 0.9777 0.9108 0.959 6.007 0.9938 0.0418 0.986 0.1196 NFD
F4 0.9869 0.9796 0.9369 0.968 6.559 0.9882 0.0487 0.987 0.1437 NFD
F5 0.9969 0.9749 0.9301 0.961 7.066 0.9971 0.0572 0.995 0.1625 NFD
F6 0.9917 0.9906 0.9066 0.969 5.921 0.9954 0.0405 0.991 0.1231 NFD
F7 0.9974 0.9939 0.7280 0.963 6.401 0.9984 0.0522 0.996 0.1067 NFD
F8 0.9897 0.9967 0.7341 0.968 5.206 0.9935 0.0350 0.988 0.1067 NFD
F9 0.9916 0.9977 0.7284 0.969 5.188 0.9951 0.0350 0.988 0.1071 NFD
F10 0.9876 0.9972 0.8157 0.984 8.003 0.9409 0.0876 0.988 0.2196 NFD
NFD- NONFICKIAN DIFFUSION
Table No: 17
COMPARISON ON INVITRO RELEASE OF RAMIPRIL NIOSOMES (SPAN 60 1:1)
WITH AND WITHOUT CHARGE INDUCING AGENTS.
TIME IN HOURS
CUMULATIVE % DRUG RELEASE±SD*
F1 F11(STR) F12(DCP)
0 0 ± 0 0 ± 0 0 ± 0
0.25 0 ± 0 1.10 ± 0.67 1.30 ± 1.51
0.5 0 ± 0 2.30 ± 0.96 2.60 ± 1.21
0.75 0 ± 0 3.90 ± 1.80 3.90 ± 0.80
1.0 4.1 ± 0.24 5.50 ± 1.09 8.20± 1.02
1.5 7.7 ± 1.71 8.30 ± 0.87 11.6 ± 0.98
2.0 11.3 ± 1.75 12.2 ± 0.96 15.8 ± 1.80
2.5 15.9 ± 1.67 14.6 ± 1.46 20.9 ± 1.53
3.0 19.7 ± 2.54 17.3 ± 1.07 23.8 ± 2.02
3.5 24.5 ± 2.01 19.5 ± 2.48 28.5 ± 1.40
4.0 26.7 ± 1.76 20.5 ± 0.75 33.4 ± 1.54
4.5 29.3 ± 1.10 22.6 ± 1.60 36.0 ± 1.72
5.0 31.4 ± 1.95 24.5 ± 1.60 39.0 ± 1.65
5.5 33.9 ± 0.60 27.8 ± 0.40 40.5 ± 0.96
6.0 34.8 ± 0.40 32.1 ± 1.50 42.6 ± 0.47
6.5 37.2 ± 1.04 35.7 ± 1.85 45.7 ± 1.18
7.0 39.2 ± 0.94 39.2 ± 1.34 49.8 ± 1.07
7.5 42.6 ± 0.58 42.2 ± 1.17 52.8 ± 0.94
8.0 44.0 ± 1.16 45.4 ± 1.00 56.8 ± 1.95
9.0 46.5 ± 1.28 49.0 ± 1.60 59.0 ± 0.96
10.0 49.7 ± 1.19 52.8 ± 1.10 60.3 ± 1.15
11.0 52.1 ± 0.02 55.3 ± 1.00 63.2 ± 1.98
12.0 54.5 ± 0.65 58.5 ± 1.50 67.4 ± 1.57
n=3*    STR- Stearylamine   DCP- Dicetyl phosphate.
Table no: 19
STABILITY STUDIES OF NIOSOMES CONTAINING SPAN 60 (1:1)
S.NO WEEK
% ENTRAPMENT EFFICIENCY
AT 60% RH±5% RH
4±20C 25±20 C
1. 0 35.05 35.05
2. 1 35.00 34.54
3. 2 34.88 33.21
4. 3 34.29 32.44
5. 4 33.81 31.07
Figure: 10 DETERMINATION OF λ max OF RAMIPRIL IN PHOSPHATE BUFFERED SALINE PH- 7.4.
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Figure- 11
CALIBRATION OF RAMIPRIL IN PBS (pH 7.4) AT λmax 207nm
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Figure- 12
COMPARISON OF ENTRAPMENT EFFICIENCIES OF RAMIPRIL NIOSOMES.
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Figure- 13
COMPARISON OF INVITRO RELEASE OF RAMIPRIL NIOSOMES CONTAINING
SPAN 60 AT DIFFERENT RATIOS.
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Figure: 15 a.
PARTICLE SIZE DISTRIBUTION F1
(SONICATION TIME= 0 MINUTES)
                         
Figure: 15 b.
PARTICLE SIZE DISTRIBUTION F1
(SONICATION TIME= 1 MINUTE)
 
Figure: 15 c.
PARTICLE SIZE DISTRIBUTION F1
(SONICATION TIME= 2 MINUTES)
Figure: 15 d.
PARTICLE SIZE DISTRIBUTION F1
(SONICATION TIME= 3 MINUTES)
Figure: 15 e.
PARTICLE SIZE DISTRIBUTION F1
(SONICATION TIME= 4 MINUTES)
Figure: 15 f.
PARTICLE SIZE DISTRIBUTION F1
(SONICATION TIME= 5 MINUTES)
EFFECT OF OSMOTIC SHOCK
                 [A]        
[B]    
[C]   
Figure: 16 [A] - HYPERTONIC (1.6% NaCl)    [B]- HYPOTONIC (0.5% NaCl)              
[C]- ISOTONIC (0.9% NaCl)
A)
B)
C)
D)
E)
F)
Figure: 28. DSC thermograms are as follows, A) Ramipril; B) Cholesterol; C) Span 40; D) Span
60; E) Formulation containing Span 40 and F) Formulation containing Span 60.
Figure : 20 a.
Particle size distribution (F12) at Malvern zeta sizer.
Figure : 20 b.
Particle size distribution (F12) at Malvern zeta sizer.
Figure : 21.
Zeta potential mesurement (F12) at Malvern zeta sizer.
Figure: 22
SEM Photograph of F1
                            
Figure: 23. FT-IR SPECTROSCOPY OF PURE DRUG- RAMIPRIL.

Figure: 24a. FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 20.

Figure: 24b.COMPARISON OF FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 20 WITH RAMIPRIL.
Fi
gure: 25a. FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 40

Figure: 25b.  COMPARISON OF FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 40 WITH RAMIPRIL.

Figure: 26a. FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 60.

Figure: 26b. COMPARISON OF FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 60 WITH RAMIPRIL.

Figure: 27a. FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 80.

Figure: 27b. COMPARISON OF FT-IR SPECTROSCOPY OF FORMULATION CONTAINING SPAN 80 WITH RAMIPRIL.
 
Figure- 14
COMPARISON OF INVITRO RELEASE OF RAMIPRIL NIOSOMES
CONTAINING DIFFERENT SURFACTANTS AT 1:1 RATIO.
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Figure- 17
COMPARISON OF INVITRO RELEASE OF RAMIPRIL NIOSOME
SPAN 60 1:1 WITH AND WITHOUT CHARGE INDUCING AGENTS.
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       Figure - 18
COMPARISON OF INVITRO RELEASE OF RAMIPRIL DRUG SOLUTION,
NIOSOME F1 (SPAN 60 1:1) AND F12 (WITH DCP).
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Figure - 19
COMPARISON OF INVITRO RELEASE STUDIES OF RAMIPRIL FORMULATIONS
Figure : 29.
STABILITY STUDIES OF RAMIPRIL NIOSOMES AT TWO DIFFERENT TEMPERATURES.
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